nifedipine	ethinyl estradiol	64	64	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  		none	none	none	none
nifedipine	norethindrone	64	64	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  		none	none	none	none
nifedipine	rosiglitazone	64	65	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	none	none	none
nifedipine	rosiglitazone	64	66	false	none	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	none	none	none
nifedipine	rosiglitazone	64	63	false	none	In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  		none	none	none	none
nifedipine	rosiglitazone	64	62	false	none	12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  		none	none	none	none
nifedipine	Gemfibrozil	64	65	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	none	none	none
nifedipine	Gemfibrozil	64	66	false	none	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	none	none	none
nifedipine	gemfibrozil	64	65	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	none	none	none
nifedipine	gemfibrozil	64	66	false	none	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	none	none	none
nifedipine	p450	64	62	false	none	12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  		none	none	none	none
nifedipine	AVANDIA	64	64	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  		none	none	none	none
nifedipine	Rosiglitazone	64	65	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	84108	none	C089730
nifedipine	Rosiglitazone	64	65	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	84108	none	C089730
nifedipine	Rosiglitazone	64	66	false	none	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	84108	none	C089730
nifedipine	Rosiglitazone	64	66	false	none	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	84108	none	C089730
nifedipine	Rosiglitazone	64	63	false	none	In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  		none	84108	none	C089730
nifedipine	Rosiglitazone	64	63	false	none	In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  		none	84108	none	C089730
nifedipine	Rosiglitazone	64	62	false	none	12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  		none	84108	none	C089730
nifedipine	Rosiglitazone	64	62	false	none	12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  		none	84108	none	C089730
ethinyl estradiol	norethindrone	64	64	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  		none	none	none	none
ethinyl estradiol	rosiglitazone	64	65	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	none	none	none
ethinyl estradiol	rosiglitazone	64	66	false	none	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	none	none	none
ethinyl estradiol	rosiglitazone	64	63	false	none	In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  		none	none	none	none
ethinyl estradiol	rosiglitazone	64	62	false	none	12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  		none	none	none	none
ethinyl estradiol	Gemfibrozil	64	65	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	none	none	none
ethinyl estradiol	Gemfibrozil	64	66	false	none	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	none	none	none
ethinyl estradiol	gemfibrozil	64	65	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	none	none	none
ethinyl estradiol	gemfibrozil	64	66	false	none	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	none	none	none
ethinyl estradiol	p450	64	62	false	none	12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  		none	none	none	none
ethinyl estradiol	AVANDIA	64	64	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  		none	none	none	none
ethinyl estradiol	Rosiglitazone	64	65	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	84108	none	C089730
ethinyl estradiol	Rosiglitazone	64	65	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	84108	none	C089730
ethinyl estradiol	Rosiglitazone	64	66	false	none	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	84108	none	C089730
ethinyl estradiol	Rosiglitazone	64	66	false	none	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	84108	none	C089730
ethinyl estradiol	Rosiglitazone	64	63	false	none	In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  		none	84108	none	C089730
ethinyl estradiol	Rosiglitazone	64	63	false	none	In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  		none	84108	none	C089730
ethinyl estradiol	Rosiglitazone	64	62	false	none	12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  		none	84108	none	C089730
ethinyl estradiol	Rosiglitazone	64	62	false	none	12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  		none	84108	none	C089730
Glimepiride	Glyburide	70	68	false	none	Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  		none	none	none	none
Glimepiride	Glyburide	70	69	false	none	In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  		none	none	none	none
Glimepiride	Glyburide	71	69	false	none	In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  		none	none	none	none
Glimepiride	rosiglitazone	70	72	true	negative	Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	none	none	none
Glimepiride	rosiglitazone	71	72	true	negative	No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	none	none	none
Glimepiride	Metformin	70	72	true	negative	Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	none	none	none
Glimepiride	Metformin	71	72	true	negative	No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	none	none	none
Glimepiride	Acarbose	71	73	true	negative	No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  		none	none	none	none
Glimepiride	glyburide	70	68	false	none	Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  		none	none	none	none
Glimepiride	glyburide	70	69	false	none	In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  		none	none	none	none
Glimepiride	glyburide	71	69	false	none	In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  		none	none	none	none
Glimepiride	metformin	70	72	true	negative	Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	none	none	none
Glimepiride	metformin	71	72	true	negative	No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	none	none	none
Glimepiride	AVANDIA	70	68	false	none	Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  		none	none	none	none
Glimepiride	AVANDIA	70	69	false	none	In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  		none	none	none	none
Glimepiride	AVANDIA	70	70	false	none	Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  		none	none	none	none
Glimepiride	AVANDIA	70	71	false	none	Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  		none	none	none	none
Glimepiride	AVANDIA	70	72	true	negative	Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	none	none	none
Glimepiride	AVANDIA	71	69	false	none	In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  		none	none	none	none
Glimepiride	AVANDIA	71	70	false	none	Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  		none	none	none	none
Glimepiride	AVANDIA	71	71	false	none	No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  		none	none	none	none
Glimepiride	AVANDIA	71	72	true	negative	No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	none	none	none
Glimepiride	AVANDIA	71	73	true	negative	No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  		none	none	none	none
Glimepiride	glimepiride	70	70	false	none	Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  		none	none	none	none
Glimepiride	glimepiride	70	71	false	none	Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  		none	none	none	none
Glimepiride	glimepiride	71	70	false	none	Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  		none	none	none	none
Glimepiride	glimepiride	71	71	false	none	No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  		none	none	none	none
Glimepiride	acarbose	71	73	true	negative	No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  		none	none	none	none
Glimepiride	Rosiglitazone	70	72	true	negative	Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	84108	none	C089730
Glimepiride	Rosiglitazone	70	72	true	negative	Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	84108	none	C089730
Glimepiride	Rosiglitazone	71	72	true	negative	No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	84108	none	C089730
Glimepiride	Rosiglitazone	71	72	true	negative	No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	84108	none	C089730
Warfarin	Digoxin	75	74	true	negative	Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  		none	none	none	none
Warfarin	rosiglitazone	75	77	true	negative	Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	none	none	none
Warfarin	Ranitidine	75	77	true	negative	Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	none	none	none
Warfarin	alcohol	75	76	false	none	Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  		none	none	none	none
Warfarin	warfarin	75	75	false	none	Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  		none	none	none	none
Warfarin	digoxin	75	74	true	negative	Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  		none	none	none	none
Warfarin	Ethanol	75	76	false	none	Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  		none	none	none	none
Warfarin	Acarbose	75	73	true	negative	Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  		none	none	none	none
Warfarin	AVANDIA	75	76	false	none	Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  		none	none	none	none
Warfarin	AVANDIA	75	73	true	negative	Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  		none	none	none	none
Warfarin	AVANDIA	75	74	true	negative	Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  		none	none	none	none
Warfarin	AVANDIA	75	75	false	none	Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  		none	none	none	none
Warfarin	acarbose	75	73	true	negative	Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  		none	none	none	none
Warfarin	ranitidine	75	77	true	negative	Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	none	none	none
Warfarin	Rosiglitazone	75	77	true	negative	Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	84108	none	C089730
Warfarin	Rosiglitazone	75	77	true	negative	Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	84108	none	C089730
Digoxin	rosiglitazone	74	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  		none	none	none	none
Digoxin	Metformin	74	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  		none	none	none	none
Digoxin	alcohol	74	76	true	negative	Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  		none	none	none	none
Digoxin	warfarin	74	75	true	negative	Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  		none	none	none	none
Digoxin	digoxin	74	74	true	negative	Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  		none	none	none	none
Digoxin	Ethanol	74	76	true	negative	Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  		none	none	none	none
Digoxin	Acarbose	74	73	true	negative	Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  		none	none	none	none
Digoxin	metformin	74	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  		none	none	none	none
Digoxin	AVANDIA	74	76	true	negative	Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  		none	none	none	none
Digoxin	AVANDIA	74	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  		none	none	none	none
Digoxin	AVANDIA	74	73	true	negative	Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  		none	none	none	none
Digoxin	AVANDIA	74	74	true	negative	Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  		none	none	none	none
Digoxin	AVANDIA	74	75	true	negative	Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  		none	none	none	none
Digoxin	acarbose	74	73	true	negative	Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  		none	none	none	none
Digoxin	Rosiglitazone	74	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  		none	84108	none	C089730
Digoxin	Rosiglitazone	74	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  		none	84108	none	C089730
norethindrone	rosiglitazone	64	65	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	none	none	none
norethindrone	rosiglitazone	64	66	false	none	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	none	none	none
norethindrone	rosiglitazone	64	63	false	none	In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  		none	none	none	none
norethindrone	rosiglitazone	64	62	false	none	12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  		none	none	none	none
norethindrone	Gemfibrozil	64	65	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	none	none	none
norethindrone	Gemfibrozil	64	66	false	none	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	none	none	none
norethindrone	gemfibrozil	64	65	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	none	none	none
norethindrone	gemfibrozil	64	66	false	none	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	none	none	none
norethindrone	p450	64	62	false	none	12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  		none	none	none	none
norethindrone	AVANDIA	64	64	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  		none	none	none	none
norethindrone	Rosiglitazone	64	65	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	84108	none	C089730
norethindrone	Rosiglitazone	64	65	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	84108	none	C089730
norethindrone	Rosiglitazone	64	66	false	none	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	84108	none	C089730
norethindrone	Rosiglitazone	64	66	false	none	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	84108	none	C089730
norethindrone	Rosiglitazone	64	63	false	none	In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  		none	84108	none	C089730
norethindrone	Rosiglitazone	64	63	false	none	In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  		none	84108	none	C089730
norethindrone	Rosiglitazone	64	62	false	none	12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  		none	84108	none	C089730
norethindrone	Rosiglitazone	64	62	false	none	12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  		none	84108	none	C089730
Glyburide	rosiglitazone	68	66	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  		none	none	none	none
Glyburide	rosiglitazone	68	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  		none	none	none	none
Glyburide	rosiglitazone	69	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  		none	none	none	none
Glyburide	rosiglitazone	67	65	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
Glyburide	rosiglitazone	67	66	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
Glyburide	rosiglitazone	67	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
Glyburide	rosiglitazone	24	25	false	none	The changes in triglycerides during therapy with AVANDIA were variable and were generally not statistically different from placebo or glyburide controls.  12.3 Pharmacokinetics    Maximum plasma concentration (Cmax) and the area under the curve (AUC) of rosiglitazone increase in a dose-proportional manner over the therapeutic dose range (Table 8).  		none	none	none	none
Glyburide	Gemfibrozil	68	66	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  		none	none	none	none
Glyburide	Gemfibrozil	67	65	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
Glyburide	Gemfibrozil	67	66	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
Glyburide	Rifampin	68	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  		none	none	none	none
Glyburide	Rifampin	69	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  		none	none	none	none
Glyburide	Rifampin	67	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
Glyburide	glyburide	68	68	true	positive	Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  		none	none	none	none
Glyburide	glyburide	68	69	true	positive	Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  		none	none	none	none
Glyburide	glyburide	68	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  		none	none	none	none
Glyburide	glyburide	69	68	true	positive	Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  		none	none	none	none
Glyburide	glyburide	69	69	false	none	In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  		none	none	none	none
Glyburide	glyburide	69	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  		none	none	none	none
Glyburide	glyburide	19	19	false	none	Because of the temporal nature of lipid changes, the 52-week glyburide-controlled study is most pertinent to assess long-term effects on lipids.  		none	none	none	none
Glyburide	glyburide	19	21	false	none	Because of the temporal nature of lipid changes, the 52-week glyburide-controlled study is most pertinent to assess long-term effects on lipids.  At baseline, week 26, and week 52, mean LDL/HDL ratios were 3.1, 3.2, and 3.0, respectively, for AVANDIA 4 mg twice daily.  The corresponding values for glyburide were 3.2, 3.1, and 2.9.  		none	none	none	none
Glyburide	glyburide	21	19	false	none	Because of the temporal nature of lipid changes, the 52-week glyburide-controlled study is most pertinent to assess long-term effects on lipids.  At baseline, week 26, and week 52, mean LDL/HDL ratios were 3.1, 3.2, and 3.0, respectively, for AVANDIA 4 mg twice daily.  The corresponding values for glyburide were 3.2, 3.1, and 2.9.  		none	none	none	none
Glyburide	glyburide	21	21	false	none	The corresponding values for glyburide were 3.2, 3.1, and 2.9.  		none	none	none	none
Glyburide	glyburide	21	22	false	none	The corresponding values for glyburide were 3.2, 3.1, and 2.9.  The differences in change from baseline between AVANDIA and glyburide at week 52 were statistically significant.  		none	none	none	none
Glyburide	glyburide	67	68	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  		none	none	none	none
Glyburide	glyburide	67	69	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  		none	none	none	none
Glyburide	glyburide	67	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
Glyburide	glyburide	22	21	false	none	The corresponding values for glyburide were 3.2, 3.1, and 2.9.  The differences in change from baseline between AVANDIA and glyburide at week 52 were statistically significant.  		none	none	none	none
Glyburide	glyburide	22	22	false	none	The differences in change from baseline between AVANDIA and glyburide at week 52 were statistically significant.  		none	none	none	none
Glyburide	glyburide	22	24	false	none	The differences in change from baseline between AVANDIA and glyburide at week 52 were statistically significant.  The pattern of LDL and HDL changes following therapy with AVANDIA in combination with other hypoglycemic agents were generally similar to those seen with AVANDIA in monotherapy.  The changes in triglycerides during therapy with AVANDIA were variable and were generally not statistically different from placebo or glyburide controls.  		none	none	none	none
Glyburide	glyburide	24	22	false	none	The differences in change from baseline between AVANDIA and glyburide at week 52 were statistically significant.  The pattern of LDL and HDL changes following therapy with AVANDIA in combination with other hypoglycemic agents were generally similar to those seen with AVANDIA in monotherapy.  The changes in triglycerides during therapy with AVANDIA were variable and were generally not statistically different from placebo or glyburide controls.  		none	none	none	none
Glyburide	glyburide	24	24	false	none	The changes in triglycerides during therapy with AVANDIA were variable and were generally not statistically different from placebo or glyburide controls.  		none	none	none	none
Glyburide	glyburide	15	15	false	none	These changes were statistically significantly different from placebo or glyburide controls (Table 7).  		none	none	none	none
Glyburide	gemfibrozil	68	66	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  		none	none	none	none
Glyburide	gemfibrozil	67	65	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
Glyburide	gemfibrozil	67	66	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
Glyburide	AVANDIA	68	68	true	positive	Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  		none	none	none	none
Glyburide	AVANDIA	68	69	true	positive	Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  		none	none	none	none
Glyburide	AVANDIA	68	70	false	none	Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  		none	none	none	none
Glyburide	AVANDIA	68	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  		none	none	none	none
Glyburide	AVANDIA	69	68	true	positive	Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  		none	none	none	none
Glyburide	AVANDIA	69	69	false	none	In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  		none	none	none	none
Glyburide	AVANDIA	69	70	false	none	In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  		none	none	none	none
Glyburide	AVANDIA	69	71	false	none	In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  		none	none	none	none
Glyburide	AVANDIA	69	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  		none	none	none	none
Glyburide	AVANDIA	19	20	false	none	Because of the temporal nature of lipid changes, the 52-week glyburide-controlled study is most pertinent to assess long-term effects on lipids.  At baseline, week 26, and week 52, mean LDL/HDL ratios were 3.1, 3.2, and 3.0, respectively, for AVANDIA 4 mg twice daily.  		none	none	none	none
Glyburide	AVANDIA	21	20	false	none	At baseline, week 26, and week 52, mean LDL/HDL ratios were 3.1, 3.2, and 3.0, respectively, for AVANDIA 4 mg twice daily.  The corresponding values for glyburide were 3.2, 3.1, and 2.9.  		none	none	none	none
Glyburide	AVANDIA	21	23	false	none	The corresponding values for glyburide were 3.2, 3.1, and 2.9.  The differences in change from baseline between AVANDIA and glyburide at week 52 were statistically significant.  The pattern of LDL and HDL changes following therapy with AVANDIA in combination with other hypoglycemic agents were generally similar to those seen with AVANDIA in monotherapy.  		none	none	none	none
Glyburide	AVANDIA	21	22	false	none	The corresponding values for glyburide were 3.2, 3.1, and 2.9.  The differences in change from baseline between AVANDIA and glyburide at week 52 were statistically significant.  		none	none	none	none
Glyburide	AVANDIA	67	68	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  		none	none	none	none
Glyburide	AVANDIA	67	69	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  		none	none	none	none
Glyburide	AVANDIA	67	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
Glyburide	AVANDIA	22	20	false	none	At baseline, week 26, and week 52, mean LDL/HDL ratios were 3.1, 3.2, and 3.0, respectively, for AVANDIA 4 mg twice daily.  The corresponding values for glyburide were 3.2, 3.1, and 2.9.  The differences in change from baseline between AVANDIA and glyburide at week 52 were statistically significant.  		none	none	none	none
Glyburide	AVANDIA	22	23	false	none	The differences in change from baseline between AVANDIA and glyburide at week 52 were statistically significant.  The pattern of LDL and HDL changes following therapy with AVANDIA in combination with other hypoglycemic agents were generally similar to those seen with AVANDIA in monotherapy.  		none	none	none	none
Glyburide	AVANDIA	22	22	false	none	The differences in change from baseline between AVANDIA and glyburide at week 52 were statistically significant.  		none	none	none	none
Glyburide	AVANDIA	22	24	false	none	The differences in change from baseline between AVANDIA and glyburide at week 52 were statistically significant.  The pattern of LDL and HDL changes following therapy with AVANDIA in combination with other hypoglycemic agents were generally similar to those seen with AVANDIA in monotherapy.  The changes in triglycerides during therapy with AVANDIA were variable and were generally not statistically different from placebo or glyburide controls.  		none	none	none	none
Glyburide	AVANDIA	24	23	false	none	The pattern of LDL and HDL changes following therapy with AVANDIA in combination with other hypoglycemic agents were generally similar to those seen with AVANDIA in monotherapy.  The changes in triglycerides during therapy with AVANDIA were variable and were generally not statistically different from placebo or glyburide controls.  		none	none	none	none
Glyburide	AVANDIA	24	22	false	none	The differences in change from baseline between AVANDIA and glyburide at week 52 were statistically significant.  The pattern of LDL and HDL changes following therapy with AVANDIA in combination with other hypoglycemic agents were generally similar to those seen with AVANDIA in monotherapy.  The changes in triglycerides during therapy with AVANDIA were variable and were generally not statistically different from placebo or glyburide controls.  		none	none	none	none
Glyburide	AVANDIA	24	24	false	none	The changes in triglycerides during therapy with AVANDIA were variable and were generally not statistically different from placebo or glyburide controls.  		none	none	none	none
Glyburide	AVANDIA	15	13	false	none	12.2 Pharmacodynamics    Patients with lipid abnormalities were not excluded from clinical trials of AVANDIA.  In all 26-week controlled trials, across the recommended dose range, AVANDIA as monotherapy was associated with increases in total cholesterol, LDL, and HDL and decreases in free fatty acids.  These changes were statistically significantly different from placebo or glyburide controls (Table 7).  		none	none	none	none
Glyburide	AVANDIA	15	14	false	none	In all 26-week controlled trials, across the recommended dose range, AVANDIA as monotherapy was associated with increases in total cholesterol, LDL, and HDL and decreases in free fatty acids.  These changes were statistically significantly different from placebo or glyburide controls (Table 7).  		none	none	none	none
Glyburide	AVANDIA	15	16	false	none	These changes were statistically significantly different from placebo or glyburide controls (Table 7).  Increases in LDL occurred primarily during the first 1 to 2 months of therapy with AVANDIA and LDL levels remained elevated above baseline throughout the trials.  		none	none	none	none
Glyburide	glimepiride	68	70	false	none	Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  		none	none	none	none
Glyburide	glimepiride	69	70	false	none	In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  		none	none	none	none
Glyburide	glimepiride	69	71	false	none	In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  		none	none	none	none
Glyburide	cholesterol	15	14	false	none	In all 26-week controlled trials, across the recommended dose range, AVANDIA as monotherapy was associated with increases in total cholesterol, LDL, and HDL and decreases in free fatty acids.  These changes were statistically significantly different from placebo or glyburide controls (Table 7).  		none	none	none	none
Glyburide	Rosiglitazone	68	66	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  		none	84108	none	C089730
Glyburide	Rosiglitazone	68	66	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  		none	84108	none	C089730
Glyburide	Rosiglitazone	68	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  		none	84108	none	C089730
Glyburide	Rosiglitazone	68	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  		none	84108	none	C089730
Glyburide	Rosiglitazone	69	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  		none	84108	none	C089730
Glyburide	Rosiglitazone	69	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  		none	84108	none	C089730
Glyburide	Rosiglitazone	67	65	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
Glyburide	Rosiglitazone	67	65	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
Glyburide	Rosiglitazone	67	66	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
Glyburide	Rosiglitazone	67	66	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
Glyburide	Rosiglitazone	67	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
Glyburide	Rosiglitazone	67	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
Glyburide	Rosiglitazone	24	25	false	none	The changes in triglycerides during therapy with AVANDIA were variable and were generally not statistically different from placebo or glyburide controls.  12.3 Pharmacokinetics    Maximum plasma concentration (Cmax) and the area under the curve (AUC) of rosiglitazone increase in a dose-proportional manner over the therapeutic dose range (Table 8).  		none	84108	none	C089730
Glyburide	Rosiglitazone	24	25	false	none	The changes in triglycerides during therapy with AVANDIA were variable and were generally not statistically different from placebo or glyburide controls.  12.3 Pharmacokinetics    Maximum plasma concentration (Cmax) and the area under the curve (AUC) of rosiglitazone increase in a dose-proportional manner over the therapeutic dose range (Table 8).  		none	84108	none	C089730
rosiglitazone	Metformin	72	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	none	none	none
rosiglitazone	Metformin	43	45	false	none	Special Populations    Geriatric    Results of the population pharmacokinetic analysis (n = 716 <65 years; n = 331 ≥65 years) showed that age does not significantly affect the pharmacokinetics of rosiglitazone.  Gender    Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642).  As monotherapy and in combination with metformin, AVANDIA improved glycemic control in both males and females.  		none	none	none	none
rosiglitazone	Metformin	44	46	false	none	Gender    Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642).  As monotherapy and in combination with metformin, AVANDIA improved glycemic control in both males and females.  In metformin combination studies, efficacy was demonstrated with no gender differences in glycemic response.  		none	none	none	none
rosiglitazone	Metformin	44	45	false	none	Gender    Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642).  As monotherapy and in combination with metformin, AVANDIA improved glycemic control in both males and females.  		none	none	none	none
rosiglitazone	Metformin	58	60	false	none	Renal Impairment    There are no clinically relevant differences in the pharmacokinetics of rosiglitazone in patients with mild to severe renal impairment or in hemodialysis-dependent patients compared to subjects with normal renal function.  No dosage adjustment is therefore required in such patients receiving AVANDIA.  Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  		none	none	none	none
rosiglitazone	Metformin	62	60	false	none	Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  		none	none	none	none
rosiglitazone	Metformin	61	60	false	none	Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  		none	none	none	none
rosiglitazone	Gemfibrozil	65	65	true	positive	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	none	none	none
rosiglitazone	Gemfibrozil	65	66	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	none	none	none
rosiglitazone	Gemfibrozil	66	65	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	none	none	none
rosiglitazone	Gemfibrozil	66	66	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	none	none	none
rosiglitazone	Gemfibrozil	67	65	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
rosiglitazone	Gemfibrozil	67	66	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
rosiglitazone	Gemfibrozil	63	65	true	positive	In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	none	none	none
rosiglitazone	Ranitidine	77	77	true	negative	Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	none	none	none
rosiglitazone	Ranitidine	78	77	true	negative	Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  These results suggest that the absorption of oral rosiglitazone is not altered in conditions accompanied by increases in gastrointestinal pH.  		none	none	none	none
rosiglitazone	alcohol	77	76	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	none	none	none
rosiglitazone	alcohol	78	76	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  These results suggest that the absorption of oral rosiglitazone is not altered in conditions accompanied by increases in gastrointestinal pH.  		none	none	none	none
rosiglitazone	alcohol	39	39	false	none	Population Pharmacokinetics in Patients With Type 2 Diabetes    Population pharmacokinetic analyses from 3 large clinical trials including 642 men and 405 women with type 2 diabetes (aged 35 to 80 years) showed that the pharmacokinetics of rosiglitazone are not influenced by age, race, smoking, or alcohol consumption.  		none	none	none	none
rosiglitazone	alcohol	37	39	false	none	Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  The plasma half-life of [14C]related material ranged from 103 to 158 hours.  Population Pharmacokinetics in Patients With Type 2 Diabetes    Population pharmacokinetic analyses from 3 large clinical trials including 642 men and 405 women with type 2 diabetes (aged 35 to 80 years) showed that the pharmacokinetics of rosiglitazone are not influenced by age, race, smoking, or alcohol consumption.  		none	none	none	none
rosiglitazone	rosiglitazone maleate	35	37	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  		none	none	none	none
rosiglitazone	rosiglitazone maleate	39	37	false	none	Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  The plasma half-life of [14C]related material ranged from 103 to 158 hours.  Population Pharmacokinetics in Patients With Type 2 Diabetes    Population pharmacokinetic analyses from 3 large clinical trials including 642 men and 405 women with type 2 diabetes (aged 35 to 80 years) showed that the pharmacokinetics of rosiglitazone are not influenced by age, race, smoking, or alcohol consumption.  		none	none	none	none
rosiglitazone	rosiglitazone maleate	36	37	false	none	In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  		none	none	none	none
rosiglitazone	rosiglitazone maleate	37	37	true	positive	Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  		none	none	none	none
rosiglitazone	thiazolidinedione	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  		none	none	none	none
rosiglitazone	thiazolidinedione	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  		none	none	none	none
rosiglitazone	warfarin	77	75	true	negative	Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	none	none	none
rosiglitazone	Rifampin	65	67	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
rosiglitazone	Rifampin	66	67	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
rosiglitazone	Rifampin	67	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
rosiglitazone	digoxin	72	74	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  		none	none	none	none
rosiglitazone	Ethanol	77	76	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	none	none	none
rosiglitazone	Ethanol	78	76	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  These results suggest that the absorption of oral rosiglitazone is not altered in conditions accompanied by increases in gastrointestinal pH.  		none	none	none	none
rosiglitazone	Acarbose	72	73	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  		none	none	none	none
rosiglitazone	glyburide	65	67	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
rosiglitazone	glyburide	66	68	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  		none	none	none	none
rosiglitazone	glyburide	66	67	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
rosiglitazone	glyburide	67	68	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  		none	none	none	none
rosiglitazone	glyburide	67	69	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  		none	none	none	none
rosiglitazone	glyburide	67	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
rosiglitazone	glyburide	25	24	false	none	The changes in triglycerides during therapy with AVANDIA were variable and were generally not statistically different from placebo or glyburide controls.  12.3 Pharmacokinetics    Maximum plasma concentration (Cmax) and the area under the curve (AUC) of rosiglitazone increase in a dose-proportional manner over the therapeutic dose range (Table 8).  		none	none	none	none
rosiglitazone	metformin	72	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	none	none	none
rosiglitazone	metformin	43	45	false	none	Special Populations    Geriatric    Results of the population pharmacokinetic analysis (n = 716 <65 years; n = 331 ≥65 years) showed that age does not significantly affect the pharmacokinetics of rosiglitazone.  Gender    Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642).  As monotherapy and in combination with metformin, AVANDIA improved glycemic control in both males and females.  		none	none	none	none
rosiglitazone	metformin	44	46	false	none	Gender    Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642).  As monotherapy and in combination with metformin, AVANDIA improved glycemic control in both males and females.  In metformin combination studies, efficacy was demonstrated with no gender differences in glycemic response.  		none	none	none	none
rosiglitazone	metformin	44	45	false	none	Gender    Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642).  As monotherapy and in combination with metformin, AVANDIA improved glycemic control in both males and females.  		none	none	none	none
rosiglitazone	metformin	58	60	false	none	Renal Impairment    There are no clinically relevant differences in the pharmacokinetics of rosiglitazone in patients with mild to severe renal impairment or in hemodialysis-dependent patients compared to subjects with normal renal function.  No dosage adjustment is therefore required in such patients receiving AVANDIA.  Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  		none	none	none	none
rosiglitazone	metformin	62	60	false	none	Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  		none	none	none	none
rosiglitazone	metformin	61	60	false	none	Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  		none	none	none	none
rosiglitazone	gemfibrozil	65	65	true	positive	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	none	none	none
rosiglitazone	gemfibrozil	65	66	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	none	none	none
rosiglitazone	gemfibrozil	66	65	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	none	none	none
rosiglitazone	gemfibrozil	66	66	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	none	none	none
rosiglitazone	gemfibrozil	67	65	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
rosiglitazone	gemfibrozil	67	66	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
rosiglitazone	gemfibrozil	63	65	true	positive	In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	none	none	none
rosiglitazone	p450	35	36	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  		none	none	none	none
rosiglitazone	p450	36	36	false	none	In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  		none	none	none	none
rosiglitazone	p450	37	36	false	none	In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  		none	none	none	none
rosiglitazone	p450	63	62	false	none	12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  		none	none	none	none
rosiglitazone	p450	62	62	false	none	12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  		none	none	none	none
rosiglitazone	p450	61	62	false	none	Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  		none	none	none	none
rosiglitazone	AVANDIA	65	64	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	none	none	none
rosiglitazone	AVANDIA	65	67	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
rosiglitazone	AVANDIA	66	68	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  		none	none	none	none
rosiglitazone	AVANDIA	66	64	false	none	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	none	none	none
rosiglitazone	AVANDIA	66	67	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
rosiglitazone	AVANDIA	67	68	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  		none	none	none	none
rosiglitazone	AVANDIA	67	69	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  		none	none	none	none
rosiglitazone	AVANDIA	67	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
rosiglitazone	AVANDIA	77	76	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	none	none	none
rosiglitazone	AVANDIA	77	75	true	negative	Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	none	none	none
rosiglitazone	AVANDIA	78	76	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  These results suggest that the absorption of oral rosiglitazone is not altered in conditions accompanied by increases in gastrointestinal pH.  		none	none	none	none
rosiglitazone	AVANDIA	72	70	true	negative	Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	none	none	none
rosiglitazone	AVANDIA	72	71	true	negative	No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	none	none	none
rosiglitazone	AVANDIA	72	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	none	none	none
rosiglitazone	AVANDIA	72	73	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  		none	none	none	none
rosiglitazone	AVANDIA	72	74	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  		none	none	none	none
rosiglitazone	AVANDIA	12	13	true	negative	Rosiglitazone did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance.  12.2 Pharmacodynamics    Patients with lipid abnormalities were not excluded from clinical trials of AVANDIA.  		none	none	none	none
rosiglitazone	AVANDIA	12	14	true	negative	Rosiglitazone did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance.  12.2 Pharmacodynamics    Patients with lipid abnormalities were not excluded from clinical trials of AVANDIA.  In all 26-week controlled trials, across the recommended dose range, AVANDIA as monotherapy was associated with increases in total cholesterol, LDL, and HDL and decreases in free fatty acids.  		none	none	none	none
rosiglitazone	AVANDIA	25	23	false	none	The pattern of LDL and HDL changes following therapy with AVANDIA in combination with other hypoglycemic agents were generally similar to those seen with AVANDIA in monotherapy.  The changes in triglycerides during therapy with AVANDIA were variable and were generally not statistically different from placebo or glyburide controls.  12.3 Pharmacokinetics    Maximum plasma concentration (Cmax) and the area under the curve (AUC) of rosiglitazone increase in a dose-proportional manner over the therapeutic dose range (Table 8).  		none	none	none	none
rosiglitazone	AVANDIA	25	24	false	none	The changes in triglycerides during therapy with AVANDIA were variable and were generally not statistically different from placebo or glyburide controls.  12.3 Pharmacokinetics    Maximum plasma concentration (Cmax) and the area under the curve (AUC) of rosiglitazone increase in a dose-proportional manner over the therapeutic dose range (Table 8).  		none	none	none	none
rosiglitazone	AVANDIA	29	30	false	none	Administration of rosiglitazone with food resulted in no change in overall exposure (AUC), but there was an approximately 28% decrease in Cmax and a delay in Tmax (1.75 hours).  These changes are not likely to be clinically significant; therefore, AVANDIA may be administered with or without food.  		none	none	none	none
rosiglitazone	AVANDIA	31	30	false	none	These changes are not likely to be clinically significant; therefore, AVANDIA may be administered with or without food.  Distribution    The mean (CV%) oral volume of distribution (Vss/F) of rosiglitazone is approximately 17.6 (30%) liters, based on a population pharmacokinetic analysis.  		none	none	none	none
rosiglitazone	AVANDIA	32	30	false	none	These changes are not likely to be clinically significant; therefore, AVANDIA may be administered with or without food.  Distribution    The mean (CV%) oral volume of distribution (Vss/F) of rosiglitazone is approximately 17.6 (30%) liters, based on a population pharmacokinetic analysis.  Rosiglitazone is approximately 99.8% bound to plasma proteins, primarily albumin.  		none	none	none	none
rosiglitazone	AVANDIA	43	45	false	none	Special Populations    Geriatric    Results of the population pharmacokinetic analysis (n = 716 <65 years; n = 331 ≥65 years) showed that age does not significantly affect the pharmacokinetics of rosiglitazone.  Gender    Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642).  As monotherapy and in combination with metformin, AVANDIA improved glycemic control in both males and females.  		none	none	none	none
rosiglitazone	AVANDIA	44	45	false	none	Gender    Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642).  As monotherapy and in combination with metformin, AVANDIA improved glycemic control in both males and females.  		none	none	none	none
rosiglitazone	AVANDIA	51	49	false	none	Since the molecular target PPARγ is expressed in adipose tissues, this differentiating characteristic may account, at least in part, for the greater response to AVANDIA in females.  Since therapy should be individualized, no dose adjustments are necessary based on gender alone.  Hepatic Impairment    Unbound oral clearance of rosiglitazone was significantly lower in patients with moderate to severe liver disease (Child-Pugh Class B/C) compared to healthy subjects.  		none	none	none	none
rosiglitazone	AVANDIA	55	54	false	none	Therapy with AVANDIA should not be initiated if the patient exhibits clinical evidence of active liver disease or increased serum transaminase levels (ALT >2.5X upper limit of normal) at baseline [see Warnings and Precautions (5.6)].  Pediatric    Pharmacokinetic parameters of rosiglitazone in pediatric patients were established using a population pharmacokinetic analysis with sparse data from 96 pediatric patients in a single pediatric clinical trial including 33 males and 63 females with ages ranging from 10 to 17 years (weights ranging from 35 to 178.3 kg).  		none	none	none	none
rosiglitazone	AVANDIA	53	54	false	none	Elimination half-life for rosiglitazone was about 2 hours longer in patients with liver disease, compared to healthy subjects.  Therapy with AVANDIA should not be initiated if the patient exhibits clinical evidence of active liver disease or increased serum transaminase levels (ALT >2.5X upper limit of normal) at baseline [see Warnings and Precautions (5.6)].  		none	none	none	none
rosiglitazone	AVANDIA	58	59	false	none	Renal Impairment    There are no clinically relevant differences in the pharmacokinetics of rosiglitazone in patients with mild to severe renal impairment or in hemodialysis-dependent patients compared to subjects with normal renal function.  No dosage adjustment is therefore required in such patients receiving AVANDIA.  		none	none	none	none
rosiglitazone	AVANDIA	58	60	false	none	Renal Impairment    There are no clinically relevant differences in the pharmacokinetics of rosiglitazone in patients with mild to severe renal impairment or in hemodialysis-dependent patients compared to subjects with normal renal function.  No dosage adjustment is therefore required in such patients receiving AVANDIA.  Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  		none	none	none	none
rosiglitazone	AVANDIA	56	54	false	none	Therapy with AVANDIA should not be initiated if the patient exhibits clinical evidence of active liver disease or increased serum transaminase levels (ALT >2.5X upper limit of normal) at baseline [see Warnings and Precautions (5.6)].  Pediatric    Pharmacokinetic parameters of rosiglitazone in pediatric patients were established using a population pharmacokinetic analysis with sparse data from 96 pediatric patients in a single pediatric clinical trial including 33 males and 63 females with ages ranging from 10 to 17 years (weights ranging from 35 to 178.3 kg).  Population mean CL/F and V/F of rosiglitazone were 3.15 L/hr and 13.5 L, respectively.  		none	none	none	none
rosiglitazone	AVANDIA	63	64	false	none	In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  		none	none	none	none
rosiglitazone	AVANDIA	62	64	false	none	12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  		none	none	none	none
rosiglitazone	AVANDIA	62	60	false	none	Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  		none	none	none	none
rosiglitazone	AVANDIA	61	59	false	none	No dosage adjustment is therefore required in such patients receiving AVANDIA.  Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  		none	none	none	none
rosiglitazone	AVANDIA	61	60	false	none	Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  		none	none	none	none
rosiglitazone	glimepiride	72	70	true	negative	Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	none	none	none
rosiglitazone	glimepiride	72	71	true	negative	No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	none	none	none
rosiglitazone	Insulin	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  		none	none	none	none
rosiglitazone	Insulin	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.  		none	none	none	none
rosiglitazone	Insulin	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  		none	none	none	none
rosiglitazone	Insulin	2	3	false	none	Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.  		none	none	none	none
rosiglitazone	Insulin	2	4	false	none	Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.  Activation of PPARγ nuclear receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization.  		none	none	none	none
rosiglitazone	Insulin	7	6	false	none	Insulin resistance is a common feature characterizing the pathogenesis of type 2 diabetes.  The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  		none	none	none	none
rosiglitazone	Insulin	7	7	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  		none	none	none	none
rosiglitazone	Insulin	7	8	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		none	none	none	none
rosiglitazone	Insulin	7	9	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	none	none	none
rosiglitazone	Insulin	8	6	false	none	Insulin resistance is a common feature characterizing the pathogenesis of type 2 diabetes.  The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		none	none	none	none
rosiglitazone	Insulin	8	7	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		none	none	none	none
rosiglitazone	Insulin	8	8	false	none	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		none	none	none	none
rosiglitazone	Insulin	8	9	false	none	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	none	none	none
rosiglitazone	Insulin	9	7	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	none	none	none
rosiglitazone	Insulin	9	8	false	none	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	none	none	none
rosiglitazone	Insulin	9	9	false	none	In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	none	none	none
rosiglitazone	Insulin	9	11	false	none	In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue.  		none	none	none	none
rosiglitazone	Insulin	10	8	false	none	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  		none	none	none	none
rosiglitazone	Insulin	10	9	false	none	In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  		none	none	none	none
rosiglitazone	Insulin	10	11	false	none	Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue.  		none	none	none	none
rosiglitazone	Insulin	12	11	true	negative	The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue.  Rosiglitazone did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance.  		none	none	none	none
rosiglitazone	Insulin	35	35	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  		none	none	none	none
rosiglitazone	Insulin	33	35	false	none	Metabolism    Rosiglitazone is extensively metabolized with no unchanged drug excreted in the urine.  The major routes of metabolism were N-demethylation and hydroxylation, followed by conjugation with sulfate and glucuronic acid.  All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  		none	none	none	none
rosiglitazone	Insulin	36	35	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  		none	none	none	none
rosiglitazone	Insulin	37	35	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  		none	none	none	none
rosiglitazone	acarbose	72	73	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  		none	none	none	none
rosiglitazone	ranitidine	77	77	true	negative	Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	none	none	none
rosiglitazone	ranitidine	78	77	true	negative	Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  These results suggest that the absorption of oral rosiglitazone is not altered in conditions accompanied by increases in gastrointestinal pH.  		none	none	none	none
rosiglitazone	insulin	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  		none	5856	none	D007328
rosiglitazone	insulin	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  		none	5856	none	D007328
rosiglitazone	insulin	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.  		none	5856	none	D007328
rosiglitazone	insulin	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.  		none	5856	none	D007328
rosiglitazone	insulin	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  		none	5856	none	D007328
rosiglitazone	insulin	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  		none	5856	none	D007328
rosiglitazone	insulin	2	3	false	none	Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.  		none	5856	none	D007328
rosiglitazone	insulin	2	3	false	none	Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.  		none	5856	none	D007328
rosiglitazone	insulin	2	4	false	none	Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.  Activation of PPARγ nuclear receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization.  		none	5856	none	D007328
rosiglitazone	insulin	2	4	false	none	Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.  Activation of PPARγ nuclear receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization.  		none	5856	none	D007328
rosiglitazone	insulin	7	6	false	none	Insulin resistance is a common feature characterizing the pathogenesis of type 2 diabetes.  The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  		none	5856	none	D007328
rosiglitazone	insulin	7	6	false	none	Insulin resistance is a common feature characterizing the pathogenesis of type 2 diabetes.  The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  		none	5856	none	D007328
rosiglitazone	insulin	7	7	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  		none	5856	none	D007328
rosiglitazone	insulin	7	7	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  		none	5856	none	D007328
rosiglitazone	insulin	7	8	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		none	5856	none	D007328
rosiglitazone	insulin	7	8	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		none	5856	none	D007328
rosiglitazone	insulin	7	9	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	5856	none	D007328
rosiglitazone	insulin	7	9	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	5856	none	D007328
rosiglitazone	insulin	8	6	false	none	Insulin resistance is a common feature characterizing the pathogenesis of type 2 diabetes.  The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		none	5856	none	D007328
rosiglitazone	insulin	8	6	false	none	Insulin resistance is a common feature characterizing the pathogenesis of type 2 diabetes.  The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		none	5856	none	D007328
rosiglitazone	insulin	8	7	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		none	5856	none	D007328
rosiglitazone	insulin	8	7	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		none	5856	none	D007328
rosiglitazone	insulin	8	8	false	none	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		none	5856	none	D007328
rosiglitazone	insulin	8	8	false	none	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		none	5856	none	D007328
rosiglitazone	insulin	8	9	false	none	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	5856	none	D007328
rosiglitazone	insulin	8	9	false	none	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	5856	none	D007328
rosiglitazone	insulin	9	7	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	5856	none	D007328
rosiglitazone	insulin	9	7	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	5856	none	D007328
rosiglitazone	insulin	9	8	false	none	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	5856	none	D007328
rosiglitazone	insulin	9	8	false	none	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	5856	none	D007328
rosiglitazone	insulin	9	9	false	none	In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	5856	none	D007328
rosiglitazone	insulin	9	9	false	none	In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	5856	none	D007328
rosiglitazone	insulin	9	11	false	none	In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue.  		none	5856	none	D007328
rosiglitazone	insulin	9	11	false	none	In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue.  		none	5856	none	D007328
rosiglitazone	insulin	10	8	false	none	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  		none	5856	none	D007328
rosiglitazone	insulin	10	8	false	none	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  		none	5856	none	D007328
rosiglitazone	insulin	10	9	false	none	In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  		none	5856	none	D007328
rosiglitazone	insulin	10	9	false	none	In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  		none	5856	none	D007328
rosiglitazone	insulin	10	11	false	none	Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue.  		none	5856	none	D007328
rosiglitazone	insulin	10	11	false	none	Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue.  		none	5856	none	D007328
rosiglitazone	insulin	12	11	true	negative	The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue.  Rosiglitazone did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance.  		none	5856	none	D007328
rosiglitazone	insulin	12	11	true	negative	The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue.  Rosiglitazone did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance.  		none	5856	none	D007328
rosiglitazone	insulin	35	35	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  		none	5856	none	D007328
rosiglitazone	insulin	35	35	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  		none	5856	none	D007328
rosiglitazone	insulin	33	35	false	none	Metabolism    Rosiglitazone is extensively metabolized with no unchanged drug excreted in the urine.  The major routes of metabolism were N-demethylation and hydroxylation, followed by conjugation with sulfate and glucuronic acid.  All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  		none	5856	none	D007328
rosiglitazone	insulin	33	35	false	none	Metabolism    Rosiglitazone is extensively metabolized with no unchanged drug excreted in the urine.  The major routes of metabolism were N-demethylation and hydroxylation, followed by conjugation with sulfate and glucuronic acid.  All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  		none	5856	none	D007328
rosiglitazone	insulin	36	35	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  		none	5856	none	D007328
rosiglitazone	insulin	36	35	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  		none	5856	none	D007328
rosiglitazone	insulin	37	35	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  		none	5856	none	D007328
rosiglitazone	insulin	37	35	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  		none	5856	none	D007328
rosiglitazone	cholesterol	12	14	true	negative	Rosiglitazone did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance.  12.2 Pharmacodynamics    Patients with lipid abnormalities were not excluded from clinical trials of AVANDIA.  In all 26-week controlled trials, across the recommended dose range, AVANDIA as monotherapy was associated with increases in total cholesterol, LDL, and HDL and decreases in free fatty acids.  		none	none	none	none
rosiglitazone	Rosiglitazone	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	1	2	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	1	2	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	2	2	false	none	Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	2	2	false	none	Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	65	65	true	positive	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	65	65	true	positive	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	65	66	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	65	66	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	65	67	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	65	67	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	65	63	true	positive	In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	65	63	true	positive	In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	66	65	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	66	65	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	66	66	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	66	66	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	66	67	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	66	67	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	67	65	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	67	65	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	67	66	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	67	66	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	67	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	67	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	7	7	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	7	7	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	7	8	true	positive	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	7	8	true	positive	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	7	9	true	positive	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	7	9	true	positive	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	8	7	true	positive	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	8	7	true	positive	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	8	8	true	positive	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	8	8	true	positive	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	8	9	true	positive	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	8	9	true	positive	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	8	10	true	positive	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	8	10	true	positive	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	77	77	true	negative	Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	77	77	true	negative	Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	77	78	true	negative	Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  These results suggest that the absorption of oral rosiglitazone is not altered in conditions accompanied by increases in gastrointestinal pH.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	77	78	true	negative	Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  These results suggest that the absorption of oral rosiglitazone is not altered in conditions accompanied by increases in gastrointestinal pH.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	9	7	true	positive	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	9	7	true	positive	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	9	8	true	positive	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	9	8	true	positive	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	9	9	false	none	In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	9	9	false	none	In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	9	10	false	none	In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	9	10	false	none	In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	78	77	true	negative	Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  These results suggest that the absorption of oral rosiglitazone is not altered in conditions accompanied by increases in gastrointestinal pH.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	78	77	true	negative	Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  These results suggest that the absorption of oral rosiglitazone is not altered in conditions accompanied by increases in gastrointestinal pH.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	78	78	false	none	These results suggest that the absorption of oral rosiglitazone is not altered in conditions accompanied by increases in gastrointestinal pH.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	78	78	false	none	These results suggest that the absorption of oral rosiglitazone is not altered in conditions accompanied by increases in gastrointestinal pH.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	10	8	true	positive	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	10	8	true	positive	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	10	9	false	none	In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	10	9	false	none	In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	10	10	false	none	Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	10	10	false	none	Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	10	12	true	negative	Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue.  Rosiglitazone did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	10	12	true	negative	Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue.  Rosiglitazone did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	72	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	72	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	12	10	true	negative	Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue.  Rosiglitazone did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	12	10	true	negative	Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue.  Rosiglitazone did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	12	12	true	negative	Rosiglitazone did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	12	12	true	negative	Rosiglitazone did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	25	25	true	positive	12.3 Pharmacokinetics    Maximum plasma concentration (Cmax) and the area under the curve (AUC) of rosiglitazone increase in a dose-proportional manner over the therapeutic dose range (Table 8).  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	25	25	true	positive	12.3 Pharmacokinetics    Maximum plasma concentration (Cmax) and the area under the curve (AUC) of rosiglitazone increase in a dose-proportional manner over the therapeutic dose range (Table 8).  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	25	27	false	none	12.3 Pharmacokinetics    Maximum plasma concentration (Cmax) and the area under the curve (AUC) of rosiglitazone increase in a dose-proportional manner over the therapeutic dose range (Table 8).  The elimination half-life is 3 to 4 hours and is independent of dose.  Absorption    The absolute bioavailability of rosiglitazone is 99%.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	25	27	false	none	12.3 Pharmacokinetics    Maximum plasma concentration (Cmax) and the area under the curve (AUC) of rosiglitazone increase in a dose-proportional manner over the therapeutic dose range (Table 8).  The elimination half-life is 3 to 4 hours and is independent of dose.  Absorption    The absolute bioavailability of rosiglitazone is 99%.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	27	25	false	none	12.3 Pharmacokinetics    Maximum plasma concentration (Cmax) and the area under the curve (AUC) of rosiglitazone increase in a dose-proportional manner over the therapeutic dose range (Table 8).  The elimination half-life is 3 to 4 hours and is independent of dose.  Absorption    The absolute bioavailability of rosiglitazone is 99%.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	27	25	false	none	12.3 Pharmacokinetics    Maximum plasma concentration (Cmax) and the area under the curve (AUC) of rosiglitazone increase in a dose-proportional manner over the therapeutic dose range (Table 8).  The elimination half-life is 3 to 4 hours and is independent of dose.  Absorption    The absolute bioavailability of rosiglitazone is 99%.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	27	27	false	none	Absorption    The absolute bioavailability of rosiglitazone is 99%.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	27	27	false	none	Absorption    The absolute bioavailability of rosiglitazone is 99%.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	27	29	false	none	Absorption    The absolute bioavailability of rosiglitazone is 99%.  Peak plasma concentrations are observed about 1 hour after dosing.  Administration of rosiglitazone with food resulted in no change in overall exposure (AUC), but there was an approximately 28% decrease in Cmax and a delay in Tmax (1.75 hours).  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	27	29	false	none	Absorption    The absolute bioavailability of rosiglitazone is 99%.  Peak plasma concentrations are observed about 1 hour after dosing.  Administration of rosiglitazone with food resulted in no change in overall exposure (AUC), but there was an approximately 28% decrease in Cmax and a delay in Tmax (1.75 hours).  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	29	27	false	none	Absorption    The absolute bioavailability of rosiglitazone is 99%.  Peak plasma concentrations are observed about 1 hour after dosing.  Administration of rosiglitazone with food resulted in no change in overall exposure (AUC), but there was an approximately 28% decrease in Cmax and a delay in Tmax (1.75 hours).  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	29	27	false	none	Absorption    The absolute bioavailability of rosiglitazone is 99%.  Peak plasma concentrations are observed about 1 hour after dosing.  Administration of rosiglitazone with food resulted in no change in overall exposure (AUC), but there was an approximately 28% decrease in Cmax and a delay in Tmax (1.75 hours).  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	29	29	true	positive	Administration of rosiglitazone with food resulted in no change in overall exposure (AUC), but there was an approximately 28% decrease in Cmax and a delay in Tmax (1.75 hours).  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	29	29	true	positive	Administration of rosiglitazone with food resulted in no change in overall exposure (AUC), but there was an approximately 28% decrease in Cmax and a delay in Tmax (1.75 hours).  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	29	31	false	none	Administration of rosiglitazone with food resulted in no change in overall exposure (AUC), but there was an approximately 28% decrease in Cmax and a delay in Tmax (1.75 hours).  These changes are not likely to be clinically significant; therefore, AVANDIA may be administered with or without food.  Distribution    The mean (CV%) oral volume of distribution (Vss/F) of rosiglitazone is approximately 17.6 (30%) liters, based on a population pharmacokinetic analysis.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	29	31	false	none	Administration of rosiglitazone with food resulted in no change in overall exposure (AUC), but there was an approximately 28% decrease in Cmax and a delay in Tmax (1.75 hours).  These changes are not likely to be clinically significant; therefore, AVANDIA may be administered with or without food.  Distribution    The mean (CV%) oral volume of distribution (Vss/F) of rosiglitazone is approximately 17.6 (30%) liters, based on a population pharmacokinetic analysis.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	31	29	false	none	Administration of rosiglitazone with food resulted in no change in overall exposure (AUC), but there was an approximately 28% decrease in Cmax and a delay in Tmax (1.75 hours).  These changes are not likely to be clinically significant; therefore, AVANDIA may be administered with or without food.  Distribution    The mean (CV%) oral volume of distribution (Vss/F) of rosiglitazone is approximately 17.6 (30%) liters, based on a population pharmacokinetic analysis.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	31	29	false	none	Administration of rosiglitazone with food resulted in no change in overall exposure (AUC), but there was an approximately 28% decrease in Cmax and a delay in Tmax (1.75 hours).  These changes are not likely to be clinically significant; therefore, AVANDIA may be administered with or without food.  Distribution    The mean (CV%) oral volume of distribution (Vss/F) of rosiglitazone is approximately 17.6 (30%) liters, based on a population pharmacokinetic analysis.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	31	31	false	none	Distribution    The mean (CV%) oral volume of distribution (Vss/F) of rosiglitazone is approximately 17.6 (30%) liters, based on a population pharmacokinetic analysis.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	31	31	false	none	Distribution    The mean (CV%) oral volume of distribution (Vss/F) of rosiglitazone is approximately 17.6 (30%) liters, based on a population pharmacokinetic analysis.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	31	32	false	none	Distribution    The mean (CV%) oral volume of distribution (Vss/F) of rosiglitazone is approximately 17.6 (30%) liters, based on a population pharmacokinetic analysis.  Rosiglitazone is approximately 99.8% bound to plasma proteins, primarily albumin.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	31	32	false	none	Distribution    The mean (CV%) oral volume of distribution (Vss/F) of rosiglitazone is approximately 17.6 (30%) liters, based on a population pharmacokinetic analysis.  Rosiglitazone is approximately 99.8% bound to plasma proteins, primarily albumin.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	31	33	false	none	Distribution    The mean (CV%) oral volume of distribution (Vss/F) of rosiglitazone is approximately 17.6 (30%) liters, based on a population pharmacokinetic analysis.  Rosiglitazone is approximately 99.8% bound to plasma proteins, primarily albumin.  Metabolism    Rosiglitazone is extensively metabolized with no unchanged drug excreted in the urine.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	31	33	false	none	Distribution    The mean (CV%) oral volume of distribution (Vss/F) of rosiglitazone is approximately 17.6 (30%) liters, based on a population pharmacokinetic analysis.  Rosiglitazone is approximately 99.8% bound to plasma proteins, primarily albumin.  Metabolism    Rosiglitazone is extensively metabolized with no unchanged drug excreted in the urine.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	35	35	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	35	35	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	35	33	false	none	Metabolism    Rosiglitazone is extensively metabolized with no unchanged drug excreted in the urine.  The major routes of metabolism were N-demethylation and hydroxylation, followed by conjugation with sulfate and glucuronic acid.  All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	35	33	false	none	Metabolism    Rosiglitazone is extensively metabolized with no unchanged drug excreted in the urine.  The major routes of metabolism were N-demethylation and hydroxylation, followed by conjugation with sulfate and glucuronic acid.  All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	35	36	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	35	36	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	35	37	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	35	37	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	32	31	false	none	Distribution    The mean (CV%) oral volume of distribution (Vss/F) of rosiglitazone is approximately 17.6 (30%) liters, based on a population pharmacokinetic analysis.  Rosiglitazone is approximately 99.8% bound to plasma proteins, primarily albumin.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	32	31	false	none	Distribution    The mean (CV%) oral volume of distribution (Vss/F) of rosiglitazone is approximately 17.6 (30%) liters, based on a population pharmacokinetic analysis.  Rosiglitazone is approximately 99.8% bound to plasma proteins, primarily albumin.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	32	32	false	none	Rosiglitazone is approximately 99.8% bound to plasma proteins, primarily albumin.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	32	32	false	none	Rosiglitazone is approximately 99.8% bound to plasma proteins, primarily albumin.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	32	33	false	none	Rosiglitazone is approximately 99.8% bound to plasma proteins, primarily albumin.  Metabolism    Rosiglitazone is extensively metabolized with no unchanged drug excreted in the urine.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	32	33	false	none	Rosiglitazone is approximately 99.8% bound to plasma proteins, primarily albumin.  Metabolism    Rosiglitazone is extensively metabolized with no unchanged drug excreted in the urine.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	33	31	false	none	Distribution    The mean (CV%) oral volume of distribution (Vss/F) of rosiglitazone is approximately 17.6 (30%) liters, based on a population pharmacokinetic analysis.  Rosiglitazone is approximately 99.8% bound to plasma proteins, primarily albumin.  Metabolism    Rosiglitazone is extensively metabolized with no unchanged drug excreted in the urine.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	33	31	false	none	Distribution    The mean (CV%) oral volume of distribution (Vss/F) of rosiglitazone is approximately 17.6 (30%) liters, based on a population pharmacokinetic analysis.  Rosiglitazone is approximately 99.8% bound to plasma proteins, primarily albumin.  Metabolism    Rosiglitazone is extensively metabolized with no unchanged drug excreted in the urine.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	33	35	false	none	Metabolism    Rosiglitazone is extensively metabolized with no unchanged drug excreted in the urine.  The major routes of metabolism were N-demethylation and hydroxylation, followed by conjugation with sulfate and glucuronic acid.  All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	33	35	false	none	Metabolism    Rosiglitazone is extensively metabolized with no unchanged drug excreted in the urine.  The major routes of metabolism were N-demethylation and hydroxylation, followed by conjugation with sulfate and glucuronic acid.  All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	33	32	false	none	Rosiglitazone is approximately 99.8% bound to plasma proteins, primarily albumin.  Metabolism    Rosiglitazone is extensively metabolized with no unchanged drug excreted in the urine.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	33	32	false	none	Rosiglitazone is approximately 99.8% bound to plasma proteins, primarily albumin.  Metabolism    Rosiglitazone is extensively metabolized with no unchanged drug excreted in the urine.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	33	33	false	none	Metabolism    Rosiglitazone is extensively metabolized with no unchanged drug excreted in the urine.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	33	33	false	none	Metabolism    Rosiglitazone is extensively metabolized with no unchanged drug excreted in the urine.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	39	39	false	none	Population Pharmacokinetics in Patients With Type 2 Diabetes    Population pharmacokinetic analyses from 3 large clinical trials including 642 men and 405 women with type 2 diabetes (aged 35 to 80 years) showed that the pharmacokinetics of rosiglitazone are not influenced by age, race, smoking, or alcohol consumption.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	39	39	false	none	Population Pharmacokinetics in Patients With Type 2 Diabetes    Population pharmacokinetic analyses from 3 large clinical trials including 642 men and 405 women with type 2 diabetes (aged 35 to 80 years) showed that the pharmacokinetics of rosiglitazone are not influenced by age, race, smoking, or alcohol consumption.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	39	37	false	none	Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  The plasma half-life of [14C]related material ranged from 103 to 158 hours.  Population Pharmacokinetics in Patients With Type 2 Diabetes    Population pharmacokinetic analyses from 3 large clinical trials including 642 men and 405 women with type 2 diabetes (aged 35 to 80 years) showed that the pharmacokinetics of rosiglitazone are not influenced by age, race, smoking, or alcohol consumption.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	39	37	false	none	Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  The plasma half-life of [14C]related material ranged from 103 to 158 hours.  Population Pharmacokinetics in Patients With Type 2 Diabetes    Population pharmacokinetic analyses from 3 large clinical trials including 642 men and 405 women with type 2 diabetes (aged 35 to 80 years) showed that the pharmacokinetics of rosiglitazone are not influenced by age, race, smoking, or alcohol consumption.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	36	35	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	36	35	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	36	36	false	none	In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	36	36	false	none	In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	36	37	false	none	In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	36	37	false	none	In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	37	35	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	37	35	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	37	39	false	none	Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  The plasma half-life of [14C]related material ranged from 103 to 158 hours.  Population Pharmacokinetics in Patients With Type 2 Diabetes    Population pharmacokinetic analyses from 3 large clinical trials including 642 men and 405 women with type 2 diabetes (aged 35 to 80 years) showed that the pharmacokinetics of rosiglitazone are not influenced by age, race, smoking, or alcohol consumption.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	37	39	false	none	Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  The plasma half-life of [14C]related material ranged from 103 to 158 hours.  Population Pharmacokinetics in Patients With Type 2 Diabetes    Population pharmacokinetic analyses from 3 large clinical trials including 642 men and 405 women with type 2 diabetes (aged 35 to 80 years) showed that the pharmacokinetics of rosiglitazone are not influenced by age, race, smoking, or alcohol consumption.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	37	36	false	none	In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	37	36	false	none	In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	37	37	true	positive	Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	37	37	true	positive	Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	42	42	true	positive	Additionally, rosiglitazone CL/F was shown to be influenced by both weight and gender, being lower (about 15%) in female patients.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	42	42	true	positive	Additionally, rosiglitazone CL/F was shown to be influenced by both weight and gender, being lower (about 15%) in female patients.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	42	43	false	none	Additionally, rosiglitazone CL/F was shown to be influenced by both weight and gender, being lower (about 15%) in female patients.  Special Populations    Geriatric    Results of the population pharmacokinetic analysis (n = 716 <65 years; n = 331 ≥65 years) showed that age does not significantly affect the pharmacokinetics of rosiglitazone.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	42	43	false	none	Additionally, rosiglitazone CL/F was shown to be influenced by both weight and gender, being lower (about 15%) in female patients.  Special Populations    Geriatric    Results of the population pharmacokinetic analysis (n = 716 <65 years; n = 331 ≥65 years) showed that age does not significantly affect the pharmacokinetics of rosiglitazone.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	42	44	false	none	Additionally, rosiglitazone CL/F was shown to be influenced by both weight and gender, being lower (about 15%) in female patients.  Special Populations    Geriatric    Results of the population pharmacokinetic analysis (n = 716 <65 years; n = 331 ≥65 years) showed that age does not significantly affect the pharmacokinetics of rosiglitazone.  Gender    Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642).  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	42	44	false	none	Additionally, rosiglitazone CL/F was shown to be influenced by both weight and gender, being lower (about 15%) in female patients.  Special Populations    Geriatric    Results of the population pharmacokinetic analysis (n = 716 <65 years; n = 331 ≥65 years) showed that age does not significantly affect the pharmacokinetics of rosiglitazone.  Gender    Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642).  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	43	42	false	none	Additionally, rosiglitazone CL/F was shown to be influenced by both weight and gender, being lower (about 15%) in female patients.  Special Populations    Geriatric    Results of the population pharmacokinetic analysis (n = 716 <65 years; n = 331 ≥65 years) showed that age does not significantly affect the pharmacokinetics of rosiglitazone.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	43	42	false	none	Additionally, rosiglitazone CL/F was shown to be influenced by both weight and gender, being lower (about 15%) in female patients.  Special Populations    Geriatric    Results of the population pharmacokinetic analysis (n = 716 <65 years; n = 331 ≥65 years) showed that age does not significantly affect the pharmacokinetics of rosiglitazone.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	43	43	false	none	Special Populations    Geriatric    Results of the population pharmacokinetic analysis (n = 716 <65 years; n = 331 ≥65 years) showed that age does not significantly affect the pharmacokinetics of rosiglitazone.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	43	43	false	none	Special Populations    Geriatric    Results of the population pharmacokinetic analysis (n = 716 <65 years; n = 331 ≥65 years) showed that age does not significantly affect the pharmacokinetics of rosiglitazone.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	43	44	false	none	Special Populations    Geriatric    Results of the population pharmacokinetic analysis (n = 716 <65 years; n = 331 ≥65 years) showed that age does not significantly affect the pharmacokinetics of rosiglitazone.  Gender    Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642).  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	43	44	false	none	Special Populations    Geriatric    Results of the population pharmacokinetic analysis (n = 716 <65 years; n = 331 ≥65 years) showed that age does not significantly affect the pharmacokinetics of rosiglitazone.  Gender    Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642).  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	44	42	false	none	Additionally, rosiglitazone CL/F was shown to be influenced by both weight and gender, being lower (about 15%) in female patients.  Special Populations    Geriatric    Results of the population pharmacokinetic analysis (n = 716 <65 years; n = 331 ≥65 years) showed that age does not significantly affect the pharmacokinetics of rosiglitazone.  Gender    Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642).  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	44	42	false	none	Additionally, rosiglitazone CL/F was shown to be influenced by both weight and gender, being lower (about 15%) in female patients.  Special Populations    Geriatric    Results of the population pharmacokinetic analysis (n = 716 <65 years; n = 331 ≥65 years) showed that age does not significantly affect the pharmacokinetics of rosiglitazone.  Gender    Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642).  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	44	43	false	none	Special Populations    Geriatric    Results of the population pharmacokinetic analysis (n = 716 <65 years; n = 331 ≥65 years) showed that age does not significantly affect the pharmacokinetics of rosiglitazone.  Gender    Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642).  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	44	43	false	none	Special Populations    Geriatric    Results of the population pharmacokinetic analysis (n = 716 <65 years; n = 331 ≥65 years) showed that age does not significantly affect the pharmacokinetics of rosiglitazone.  Gender    Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642).  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	44	44	false	none	Gender    Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642).  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	44	44	false	none	Gender    Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642).  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	51	51	false	none	Hepatic Impairment    Unbound oral clearance of rosiglitazone was significantly lower in patients with moderate to severe liver disease (Child-Pugh Class B/C) compared to healthy subjects.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	51	51	false	none	Hepatic Impairment    Unbound oral clearance of rosiglitazone was significantly lower in patients with moderate to severe liver disease (Child-Pugh Class B/C) compared to healthy subjects.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	51	53	false	none	Hepatic Impairment    Unbound oral clearance of rosiglitazone was significantly lower in patients with moderate to severe liver disease (Child-Pugh Class B/C) compared to healthy subjects.  As a result, unbound Cmax and AUC0-inf were increased 2- and 3-fold, respectively.  Elimination half-life for rosiglitazone was about 2 hours longer in patients with liver disease, compared to healthy subjects.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	51	53	false	none	Hepatic Impairment    Unbound oral clearance of rosiglitazone was significantly lower in patients with moderate to severe liver disease (Child-Pugh Class B/C) compared to healthy subjects.  As a result, unbound Cmax and AUC0-inf were increased 2- and 3-fold, respectively.  Elimination half-life for rosiglitazone was about 2 hours longer in patients with liver disease, compared to healthy subjects.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	55	55	false	none	Pediatric    Pharmacokinetic parameters of rosiglitazone in pediatric patients were established using a population pharmacokinetic analysis with sparse data from 96 pediatric patients in a single pediatric clinical trial including 33 males and 63 females with ages ranging from 10 to 17 years (weights ranging from 35 to 178.3 kg).  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	55	55	false	none	Pediatric    Pharmacokinetic parameters of rosiglitazone in pediatric patients were established using a population pharmacokinetic analysis with sparse data from 96 pediatric patients in a single pediatric clinical trial including 33 males and 63 females with ages ranging from 10 to 17 years (weights ranging from 35 to 178.3 kg).  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	55	53	false	none	Elimination half-life for rosiglitazone was about 2 hours longer in patients with liver disease, compared to healthy subjects.  Therapy with AVANDIA should not be initiated if the patient exhibits clinical evidence of active liver disease or increased serum transaminase levels (ALT >2.5X upper limit of normal) at baseline [see Warnings and Precautions (5.6)].  Pediatric    Pharmacokinetic parameters of rosiglitazone in pediatric patients were established using a population pharmacokinetic analysis with sparse data from 96 pediatric patients in a single pediatric clinical trial including 33 males and 63 females with ages ranging from 10 to 17 years (weights ranging from 35 to 178.3 kg).  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	55	53	false	none	Elimination half-life for rosiglitazone was about 2 hours longer in patients with liver disease, compared to healthy subjects.  Therapy with AVANDIA should not be initiated if the patient exhibits clinical evidence of active liver disease or increased serum transaminase levels (ALT >2.5X upper limit of normal) at baseline [see Warnings and Precautions (5.6)].  Pediatric    Pharmacokinetic parameters of rosiglitazone in pediatric patients were established using a population pharmacokinetic analysis with sparse data from 96 pediatric patients in a single pediatric clinical trial including 33 males and 63 females with ages ranging from 10 to 17 years (weights ranging from 35 to 178.3 kg).  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	55	56	false	none	Pediatric    Pharmacokinetic parameters of rosiglitazone in pediatric patients were established using a population pharmacokinetic analysis with sparse data from 96 pediatric patients in a single pediatric clinical trial including 33 males and 63 females with ages ranging from 10 to 17 years (weights ranging from 35 to 178.3 kg).  Population mean CL/F and V/F of rosiglitazone were 3.15 L/hr and 13.5 L, respectively.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	55	56	false	none	Pediatric    Pharmacokinetic parameters of rosiglitazone in pediatric patients were established using a population pharmacokinetic analysis with sparse data from 96 pediatric patients in a single pediatric clinical trial including 33 males and 63 females with ages ranging from 10 to 17 years (weights ranging from 35 to 178.3 kg).  Population mean CL/F and V/F of rosiglitazone were 3.15 L/hr and 13.5 L, respectively.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	53	51	false	none	Hepatic Impairment    Unbound oral clearance of rosiglitazone was significantly lower in patients with moderate to severe liver disease (Child-Pugh Class B/C) compared to healthy subjects.  As a result, unbound Cmax and AUC0-inf were increased 2- and 3-fold, respectively.  Elimination half-life for rosiglitazone was about 2 hours longer in patients with liver disease, compared to healthy subjects.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	53	51	false	none	Hepatic Impairment    Unbound oral clearance of rosiglitazone was significantly lower in patients with moderate to severe liver disease (Child-Pugh Class B/C) compared to healthy subjects.  As a result, unbound Cmax and AUC0-inf were increased 2- and 3-fold, respectively.  Elimination half-life for rosiglitazone was about 2 hours longer in patients with liver disease, compared to healthy subjects.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	53	55	false	none	Elimination half-life for rosiglitazone was about 2 hours longer in patients with liver disease, compared to healthy subjects.  Therapy with AVANDIA should not be initiated if the patient exhibits clinical evidence of active liver disease or increased serum transaminase levels (ALT >2.5X upper limit of normal) at baseline [see Warnings and Precautions (5.6)].  Pediatric    Pharmacokinetic parameters of rosiglitazone in pediatric patients were established using a population pharmacokinetic analysis with sparse data from 96 pediatric patients in a single pediatric clinical trial including 33 males and 63 females with ages ranging from 10 to 17 years (weights ranging from 35 to 178.3 kg).  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	53	55	false	none	Elimination half-life for rosiglitazone was about 2 hours longer in patients with liver disease, compared to healthy subjects.  Therapy with AVANDIA should not be initiated if the patient exhibits clinical evidence of active liver disease or increased serum transaminase levels (ALT >2.5X upper limit of normal) at baseline [see Warnings and Precautions (5.6)].  Pediatric    Pharmacokinetic parameters of rosiglitazone in pediatric patients were established using a population pharmacokinetic analysis with sparse data from 96 pediatric patients in a single pediatric clinical trial including 33 males and 63 females with ages ranging from 10 to 17 years (weights ranging from 35 to 178.3 kg).  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	53	53	false	none	Elimination half-life for rosiglitazone was about 2 hours longer in patients with liver disease, compared to healthy subjects.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	53	53	false	none	Elimination half-life for rosiglitazone was about 2 hours longer in patients with liver disease, compared to healthy subjects.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	58	58	false	none	Renal Impairment    There are no clinically relevant differences in the pharmacokinetics of rosiglitazone in patients with mild to severe renal impairment or in hemodialysis-dependent patients compared to subjects with normal renal function.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	58	58	false	none	Renal Impairment    There are no clinically relevant differences in the pharmacokinetics of rosiglitazone in patients with mild to severe renal impairment or in hemodialysis-dependent patients compared to subjects with normal renal function.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	58	56	false	none	Population mean CL/F and V/F of rosiglitazone were 3.15 L/hr and 13.5 L, respectively.  These estimates of CL/F and V/F were consistent with the typical parameter estimates from a prior adult population analysis.  Renal Impairment    There are no clinically relevant differences in the pharmacokinetics of rosiglitazone in patients with mild to severe renal impairment or in hemodialysis-dependent patients compared to subjects with normal renal function.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	58	56	false	none	Population mean CL/F and V/F of rosiglitazone were 3.15 L/hr and 13.5 L, respectively.  These estimates of CL/F and V/F were consistent with the typical parameter estimates from a prior adult population analysis.  Renal Impairment    There are no clinically relevant differences in the pharmacokinetics of rosiglitazone in patients with mild to severe renal impairment or in hemodialysis-dependent patients compared to subjects with normal renal function.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	56	55	false	none	Pediatric    Pharmacokinetic parameters of rosiglitazone in pediatric patients were established using a population pharmacokinetic analysis with sparse data from 96 pediatric patients in a single pediatric clinical trial including 33 males and 63 females with ages ranging from 10 to 17 years (weights ranging from 35 to 178.3 kg).  Population mean CL/F and V/F of rosiglitazone were 3.15 L/hr and 13.5 L, respectively.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	56	55	false	none	Pediatric    Pharmacokinetic parameters of rosiglitazone in pediatric patients were established using a population pharmacokinetic analysis with sparse data from 96 pediatric patients in a single pediatric clinical trial including 33 males and 63 females with ages ranging from 10 to 17 years (weights ranging from 35 to 178.3 kg).  Population mean CL/F and V/F of rosiglitazone were 3.15 L/hr and 13.5 L, respectively.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	56	58	false	none	Population mean CL/F and V/F of rosiglitazone were 3.15 L/hr and 13.5 L, respectively.  These estimates of CL/F and V/F were consistent with the typical parameter estimates from a prior adult population analysis.  Renal Impairment    There are no clinically relevant differences in the pharmacokinetics of rosiglitazone in patients with mild to severe renal impairment or in hemodialysis-dependent patients compared to subjects with normal renal function.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	56	58	false	none	Population mean CL/F and V/F of rosiglitazone were 3.15 L/hr and 13.5 L, respectively.  These estimates of CL/F and V/F were consistent with the typical parameter estimates from a prior adult population analysis.  Renal Impairment    There are no clinically relevant differences in the pharmacokinetics of rosiglitazone in patients with mild to severe renal impairment or in hemodialysis-dependent patients compared to subjects with normal renal function.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	56	56	true	positive	Population mean CL/F and V/F of rosiglitazone were 3.15 L/hr and 13.5 L, respectively.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	56	56	true	positive	Population mean CL/F and V/F of rosiglitazone were 3.15 L/hr and 13.5 L, respectively.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	63	65	true	positive	In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	63	65	true	positive	In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	63	63	false	none	In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	63	63	false	none	In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	63	62	false	none	12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	63	62	false	none	12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	63	61	false	none	Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	63	61	false	none	Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	62	63	false	none	12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	62	63	false	none	12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	62	62	true	positive	12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	62	62	true	positive	12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	62	61	true	negative	Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	62	61	true	negative	Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	61	63	false	none	Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	61	63	false	none	Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	61	62	true	negative	Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	61	62	true	negative	Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	61	61	false	none	Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  		none	84108	none	C089730
rosiglitazone	Rosiglitazone	61	61	false	none	Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  		none	84108	none	C089730
Metformin	digoxin	72	74	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  		none	none	none	none
Metformin	Acarbose	72	73	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  		none	none	none	none
Metformin	metformin	72	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	none	none	none
Metformin	metformin	46	46	false	none	In metformin combination studies, efficacy was demonstrated with no gender differences in glycemic response.  		none	none	none	none
Metformin	metformin	46	45	false	none	As monotherapy and in combination with metformin, AVANDIA improved glycemic control in both males and females.  In metformin combination studies, efficacy was demonstrated with no gender differences in glycemic response.  		none	none	none	none
Metformin	metformin	60	60	false	none	Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  		none	none	none	none
Metformin	metformin	45	46	false	none	As monotherapy and in combination with metformin, AVANDIA improved glycemic control in both males and females.  In metformin combination studies, efficacy was demonstrated with no gender differences in glycemic response.  		none	none	none	none
Metformin	metformin	45	45	false	none	As monotherapy and in combination with metformin, AVANDIA improved glycemic control in both males and females.  		none	none	none	none
Metformin	p450	60	62	false	none	Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  		none	none	none	none
Metformin	AVANDIA	72	70	true	negative	Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	none	none	none
Metformin	AVANDIA	72	71	true	negative	No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	none	none	none
Metformin	AVANDIA	72	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	none	none	none
Metformin	AVANDIA	72	73	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  		none	none	none	none
Metformin	AVANDIA	72	74	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  		none	none	none	none
Metformin	AVANDIA	46	45	false	none	As monotherapy and in combination with metformin, AVANDIA improved glycemic control in both males and females.  In metformin combination studies, efficacy was demonstrated with no gender differences in glycemic response.  		none	none	none	none
Metformin	AVANDIA	60	59	false	none	No dosage adjustment is therefore required in such patients receiving AVANDIA.  Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  		none	none	none	none
Metformin	AVANDIA	60	60	false	none	Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  		none	none	none	none
Metformin	AVANDIA	45	45	false	none	As monotherapy and in combination with metformin, AVANDIA improved glycemic control in both males and females.  		none	none	none	none
Metformin	glimepiride	72	70	true	negative	Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	none	none	none
Metformin	glimepiride	72	71	true	negative	No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	none	none	none
Metformin	acarbose	72	73	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  		none	none	none	none
Metformin	Rosiglitazone	72	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	84108	none	C089730
Metformin	Rosiglitazone	72	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	84108	none	C089730
Metformin	Rosiglitazone	46	44	false	none	Gender    Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642).  As monotherapy and in combination with metformin, AVANDIA improved glycemic control in both males and females.  In metformin combination studies, efficacy was demonstrated with no gender differences in glycemic response.  		none	84108	none	C089730
Metformin	Rosiglitazone	46	44	false	none	Gender    Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642).  As monotherapy and in combination with metformin, AVANDIA improved glycemic control in both males and females.  In metformin combination studies, efficacy was demonstrated with no gender differences in glycemic response.  		none	84108	none	C089730
Metformin	Rosiglitazone	60	58	false	none	Renal Impairment    There are no clinically relevant differences in the pharmacokinetics of rosiglitazone in patients with mild to severe renal impairment or in hemodialysis-dependent patients compared to subjects with normal renal function.  No dosage adjustment is therefore required in such patients receiving AVANDIA.  Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  		none	84108	none	C089730
Metformin	Rosiglitazone	60	58	false	none	Renal Impairment    There are no clinically relevant differences in the pharmacokinetics of rosiglitazone in patients with mild to severe renal impairment or in hemodialysis-dependent patients compared to subjects with normal renal function.  No dosage adjustment is therefore required in such patients receiving AVANDIA.  Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  		none	84108	none	C089730
Metformin	Rosiglitazone	60	62	false	none	Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  		none	84108	none	C089730
Metformin	Rosiglitazone	60	62	false	none	Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  		none	84108	none	C089730
Metformin	Rosiglitazone	60	61	false	none	Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  		none	84108	none	C089730
Metformin	Rosiglitazone	60	61	false	none	Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  		none	84108	none	C089730
Metformin	Rosiglitazone	45	43	false	none	Special Populations    Geriatric    Results of the population pharmacokinetic analysis (n = 716 <65 years; n = 331 ≥65 years) showed that age does not significantly affect the pharmacokinetics of rosiglitazone.  Gender    Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642).  As monotherapy and in combination with metformin, AVANDIA improved glycemic control in both males and females.  		none	84108	none	C089730
Metformin	Rosiglitazone	45	43	false	none	Special Populations    Geriatric    Results of the population pharmacokinetic analysis (n = 716 <65 years; n = 331 ≥65 years) showed that age does not significantly affect the pharmacokinetics of rosiglitazone.  Gender    Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642).  As monotherapy and in combination with metformin, AVANDIA improved glycemic control in both males and females.  		none	84108	none	C089730
Metformin	Rosiglitazone	45	44	false	none	Gender    Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642).  As monotherapy and in combination with metformin, AVANDIA improved glycemic control in both males and females.  		none	84108	none	C089730
Metformin	Rosiglitazone	45	44	false	none	Gender    Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642).  As monotherapy and in combination with metformin, AVANDIA improved glycemic control in both males and females.  		none	84108	none	C089730
Gemfibrozil	Rifampin	65	67	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
Gemfibrozil	Rifampin	66	67	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
Gemfibrozil	glyburide	65	67	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
Gemfibrozil	glyburide	66	68	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  		none	none	none	none
Gemfibrozil	glyburide	66	67	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
Gemfibrozil	gemfibrozil	65	65	true	positive	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	none	none	none
Gemfibrozil	gemfibrozil	65	66	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	none	none	none
Gemfibrozil	gemfibrozil	66	65	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	none	none	none
Gemfibrozil	gemfibrozil	66	66	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	none	none	none
Gemfibrozil	AVANDIA	65	64	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	none	none	none
Gemfibrozil	AVANDIA	65	67	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
Gemfibrozil	AVANDIA	66	68	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  		none	none	none	none
Gemfibrozil	AVANDIA	66	64	false	none	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	none	none	none
Gemfibrozil	AVANDIA	66	67	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
Gemfibrozil	Rosiglitazone	65	65	true	positive	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	84108	none	C089730
Gemfibrozil	Rosiglitazone	65	65	true	positive	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	84108	none	C089730
Gemfibrozil	Rosiglitazone	65	66	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	84108	none	C089730
Gemfibrozil	Rosiglitazone	65	66	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	84108	none	C089730
Gemfibrozil	Rosiglitazone	65	67	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
Gemfibrozil	Rosiglitazone	65	67	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
Gemfibrozil	Rosiglitazone	65	63	true	positive	In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	84108	none	C089730
Gemfibrozil	Rosiglitazone	65	63	true	positive	In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	84108	none	C089730
Gemfibrozil	Rosiglitazone	66	65	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	84108	none	C089730
Gemfibrozil	Rosiglitazone	66	65	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	84108	none	C089730
Gemfibrozil	Rosiglitazone	66	66	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	84108	none	C089730
Gemfibrozil	Rosiglitazone	66	66	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	84108	none	C089730
Gemfibrozil	Rosiglitazone	66	67	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
Gemfibrozil	Rosiglitazone	66	67	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
Ranitidine	alcohol	77	76	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	none	none	none
Ranitidine	warfarin	77	75	true	negative	Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	none	none	none
Ranitidine	Ethanol	77	76	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	none	none	none
Ranitidine	AVANDIA	77	76	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	none	none	none
Ranitidine	AVANDIA	77	75	true	negative	Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	none	none	none
Ranitidine	ranitidine	77	77	true	negative	Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	none	none	none
Ranitidine	Rosiglitazone	77	77	true	negative	Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	84108	none	C089730
Ranitidine	Rosiglitazone	77	77	true	negative	Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	84108	none	C089730
Ranitidine	Rosiglitazone	77	78	true	negative	Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  These results suggest that the absorption of oral rosiglitazone is not altered in conditions accompanied by increases in gastrointestinal pH.  		none	84108	none	C089730
Ranitidine	Rosiglitazone	77	78	true	negative	Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  These results suggest that the absorption of oral rosiglitazone is not altered in conditions accompanied by increases in gastrointestinal pH.  		none	84108	none	C089730
alcohol	rosiglitazone maleate	39	37	false	none	Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  The plasma half-life of [14C]related material ranged from 103 to 158 hours.  Population Pharmacokinetics in Patients With Type 2 Diabetes    Population pharmacokinetic analyses from 3 large clinical trials including 642 men and 405 women with type 2 diabetes (aged 35 to 80 years) showed that the pharmacokinetics of rosiglitazone are not influenced by age, race, smoking, or alcohol consumption.  		none	none	none	none
alcohol	warfarin	76	75	false	none	Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  		none	none	none	none
alcohol	digoxin	76	74	true	negative	Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  		none	none	none	none
alcohol	Ethanol	76	76	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  		none	none	none	none
alcohol	AVANDIA	76	76	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  		none	none	none	none
alcohol	AVANDIA	76	74	true	negative	Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  		none	none	none	none
alcohol	AVANDIA	76	75	false	none	Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  		none	none	none	none
alcohol	ranitidine	76	77	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	none	none	none
alcohol	Rosiglitazone	39	39	false	none	Population Pharmacokinetics in Patients With Type 2 Diabetes    Population pharmacokinetic analyses from 3 large clinical trials including 642 men and 405 women with type 2 diabetes (aged 35 to 80 years) showed that the pharmacokinetics of rosiglitazone are not influenced by age, race, smoking, or alcohol consumption.  		none	84108	none	C089730
alcohol	Rosiglitazone	39	39	false	none	Population Pharmacokinetics in Patients With Type 2 Diabetes    Population pharmacokinetic analyses from 3 large clinical trials including 642 men and 405 women with type 2 diabetes (aged 35 to 80 years) showed that the pharmacokinetics of rosiglitazone are not influenced by age, race, smoking, or alcohol consumption.  		none	84108	none	C089730
alcohol	Rosiglitazone	39	37	false	none	Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  The plasma half-life of [14C]related material ranged from 103 to 158 hours.  Population Pharmacokinetics in Patients With Type 2 Diabetes    Population pharmacokinetic analyses from 3 large clinical trials including 642 men and 405 women with type 2 diabetes (aged 35 to 80 years) showed that the pharmacokinetics of rosiglitazone are not influenced by age, race, smoking, or alcohol consumption.  		none	84108	none	C089730
alcohol	Rosiglitazone	39	37	false	none	Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  The plasma half-life of [14C]related material ranged from 103 to 158 hours.  Population Pharmacokinetics in Patients With Type 2 Diabetes    Population pharmacokinetic analyses from 3 large clinical trials including 642 men and 405 women with type 2 diabetes (aged 35 to 80 years) showed that the pharmacokinetics of rosiglitazone are not influenced by age, race, smoking, or alcohol consumption.  		none	84108	none	C089730
alcohol	Rosiglitazone	76	77	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	84108	none	C089730
alcohol	Rosiglitazone	76	77	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	84108	none	C089730
alcohol	Rosiglitazone	76	78	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  These results suggest that the absorption of oral rosiglitazone is not altered in conditions accompanied by increases in gastrointestinal pH.  		none	84108	none	C089730
alcohol	Rosiglitazone	76	78	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  These results suggest that the absorption of oral rosiglitazone is not altered in conditions accompanied by increases in gastrointestinal pH.  		none	84108	none	C089730
rosiglitazone maleate	p450	37	36	false	none	In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  		none	none	none	none
rosiglitazone maleate	Insulin	37	35	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  		none	none	none	none
rosiglitazone maleate	insulin	37	35	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  		none	5856	none	D007328
rosiglitazone maleate	insulin	37	35	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  		none	5856	none	D007328
rosiglitazone maleate	Rosiglitazone	37	35	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  		none	84108	none	C089730
rosiglitazone maleate	Rosiglitazone	37	35	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  		none	84108	none	C089730
rosiglitazone maleate	Rosiglitazone	37	39	false	none	Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  The plasma half-life of [14C]related material ranged from 103 to 158 hours.  Population Pharmacokinetics in Patients With Type 2 Diabetes    Population pharmacokinetic analyses from 3 large clinical trials including 642 men and 405 women with type 2 diabetes (aged 35 to 80 years) showed that the pharmacokinetics of rosiglitazone are not influenced by age, race, smoking, or alcohol consumption.  		none	84108	none	C089730
rosiglitazone maleate	Rosiglitazone	37	39	false	none	Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  The plasma half-life of [14C]related material ranged from 103 to 158 hours.  Population Pharmacokinetics in Patients With Type 2 Diabetes    Population pharmacokinetic analyses from 3 large clinical trials including 642 men and 405 women with type 2 diabetes (aged 35 to 80 years) showed that the pharmacokinetics of rosiglitazone are not influenced by age, race, smoking, or alcohol consumption.  		none	84108	none	C089730
rosiglitazone maleate	Rosiglitazone	37	36	false	none	In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  		none	84108	none	C089730
rosiglitazone maleate	Rosiglitazone	37	36	false	none	In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  		none	84108	none	C089730
rosiglitazone maleate	Rosiglitazone	37	37	true	positive	Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  		none	84108	none	C089730
rosiglitazone maleate	Rosiglitazone	37	37	true	positive	Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  		none	84108	none	C089730
thiazolidinedione	Insulin	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  		none	none	none	none
thiazolidinedione	Insulin	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.  		none	none	none	none
thiazolidinedione	insulin	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  		none	5856	none	D007328
thiazolidinedione	insulin	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  		none	5856	none	D007328
thiazolidinedione	insulin	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.  		none	5856	none	D007328
thiazolidinedione	insulin	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.  		none	5856	none	D007328
thiazolidinedione	Rosiglitazone	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  		none	84108	none	C089730
thiazolidinedione	Rosiglitazone	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  		none	84108	none	C089730
thiazolidinedione	Rosiglitazone	1	2	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  		none	84108	none	C089730
thiazolidinedione	Rosiglitazone	1	2	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  		none	84108	none	C089730
warfarin	digoxin	75	74	true	negative	Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  		none	none	none	none
warfarin	Ethanol	75	76	false	none	Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  		none	none	none	none
warfarin	Acarbose	75	73	true	negative	Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  		none	none	none	none
warfarin	AVANDIA	75	76	false	none	Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  		none	none	none	none
warfarin	AVANDIA	75	73	true	negative	Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  		none	none	none	none
warfarin	AVANDIA	75	74	true	negative	Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  		none	none	none	none
warfarin	AVANDIA	75	75	false	none	Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  		none	none	none	none
warfarin	acarbose	75	73	true	negative	Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  		none	none	none	none
warfarin	ranitidine	75	77	true	negative	Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	none	none	none
warfarin	Rosiglitazone	75	77	true	negative	Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	84108	none	C089730
warfarin	Rosiglitazone	75	77	true	negative	Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	84108	none	C089730
Rifampin	glyburide	67	68	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  		none	none	none	none
Rifampin	glyburide	67	69	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  		none	none	none	none
Rifampin	glyburide	67	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
Rifampin	gemfibrozil	67	65	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
Rifampin	gemfibrozil	67	66	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
Rifampin	AVANDIA	67	68	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  		none	none	none	none
Rifampin	AVANDIA	67	69	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  		none	none	none	none
Rifampin	AVANDIA	67	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
Rifampin	Rosiglitazone	67	65	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
Rifampin	Rosiglitazone	67	65	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
Rifampin	Rosiglitazone	67	66	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
Rifampin	Rosiglitazone	67	66	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
Rifampin	Rosiglitazone	67	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
Rifampin	Rosiglitazone	67	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
digoxin	Ethanol	74	76	true	negative	Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  		none	none	none	none
digoxin	Acarbose	74	73	true	negative	Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  		none	none	none	none
digoxin	metformin	74	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  		none	none	none	none
digoxin	AVANDIA	74	76	true	negative	Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  		none	none	none	none
digoxin	AVANDIA	74	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  		none	none	none	none
digoxin	AVANDIA	74	73	true	negative	Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  		none	none	none	none
digoxin	AVANDIA	74	74	true	negative	Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  		none	none	none	none
digoxin	AVANDIA	74	75	true	negative	Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  		none	none	none	none
digoxin	acarbose	74	73	true	negative	Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  		none	none	none	none
digoxin	Rosiglitazone	74	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  		none	84108	none	C089730
digoxin	Rosiglitazone	74	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  		none	84108	none	C089730
Ethanol	AVANDIA	76	76	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  		none	none	none	none
Ethanol	AVANDIA	76	74	true	negative	Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  		none	none	none	none
Ethanol	AVANDIA	76	75	false	none	Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  		none	none	none	none
Ethanol	ranitidine	76	77	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	none	none	none
Ethanol	Rosiglitazone	76	77	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	84108	none	C089730
Ethanol	Rosiglitazone	76	77	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	84108	none	C089730
Ethanol	Rosiglitazone	76	78	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  These results suggest that the absorption of oral rosiglitazone is not altered in conditions accompanied by increases in gastrointestinal pH.  		none	84108	none	C089730
Ethanol	Rosiglitazone	76	78	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  These results suggest that the absorption of oral rosiglitazone is not altered in conditions accompanied by increases in gastrointestinal pH.  		none	84108	none	C089730
Acarbose	metformin	73	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  		none	none	none	none
Acarbose	AVANDIA	73	71	true	negative	No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  		none	none	none	none
Acarbose	AVANDIA	73	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  		none	none	none	none
Acarbose	AVANDIA	73	73	false	none	Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  		none	none	none	none
Acarbose	AVANDIA	73	74	true	negative	Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  		none	none	none	none
Acarbose	AVANDIA	73	75	true	negative	Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  		none	none	none	none
Acarbose	glimepiride	73	71	true	negative	No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  		none	none	none	none
Acarbose	acarbose	73	73	false	none	Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  		none	none	none	none
Acarbose	Rosiglitazone	73	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  		none	84108	none	C089730
Acarbose	Rosiglitazone	73	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  		none	84108	none	C089730
glyburide	gemfibrozil	68	66	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  		none	none	none	none
glyburide	gemfibrozil	67	65	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
glyburide	gemfibrozil	67	66	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
glyburide	AVANDIA	68	68	true	positive	Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  		none	none	none	none
glyburide	AVANDIA	68	69	true	positive	Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  		none	none	none	none
glyburide	AVANDIA	68	70	false	none	Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  		none	none	none	none
glyburide	AVANDIA	68	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  		none	none	none	none
glyburide	AVANDIA	69	68	true	positive	Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  		none	none	none	none
glyburide	AVANDIA	69	69	false	none	In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  		none	none	none	none
glyburide	AVANDIA	69	70	false	none	In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  		none	none	none	none
glyburide	AVANDIA	69	71	false	none	In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  		none	none	none	none
glyburide	AVANDIA	69	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  		none	none	none	none
glyburide	AVANDIA	19	20	false	none	Because of the temporal nature of lipid changes, the 52-week glyburide-controlled study is most pertinent to assess long-term effects on lipids.  At baseline, week 26, and week 52, mean LDL/HDL ratios were 3.1, 3.2, and 3.0, respectively, for AVANDIA 4 mg twice daily.  		none	none	none	none
glyburide	AVANDIA	21	20	false	none	At baseline, week 26, and week 52, mean LDL/HDL ratios were 3.1, 3.2, and 3.0, respectively, for AVANDIA 4 mg twice daily.  The corresponding values for glyburide were 3.2, 3.1, and 2.9.  		none	none	none	none
glyburide	AVANDIA	21	23	false	none	The corresponding values for glyburide were 3.2, 3.1, and 2.9.  The differences in change from baseline between AVANDIA and glyburide at week 52 were statistically significant.  The pattern of LDL and HDL changes following therapy with AVANDIA in combination with other hypoglycemic agents were generally similar to those seen with AVANDIA in monotherapy.  		none	none	none	none
glyburide	AVANDIA	21	22	false	none	The corresponding values for glyburide were 3.2, 3.1, and 2.9.  The differences in change from baseline between AVANDIA and glyburide at week 52 were statistically significant.  		none	none	none	none
glyburide	AVANDIA	67	68	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  		none	none	none	none
glyburide	AVANDIA	67	69	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  		none	none	none	none
glyburide	AVANDIA	67	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
glyburide	AVANDIA	22	20	false	none	At baseline, week 26, and week 52, mean LDL/HDL ratios were 3.1, 3.2, and 3.0, respectively, for AVANDIA 4 mg twice daily.  The corresponding values for glyburide were 3.2, 3.1, and 2.9.  The differences in change from baseline between AVANDIA and glyburide at week 52 were statistically significant.  		none	none	none	none
glyburide	AVANDIA	22	23	false	none	The differences in change from baseline between AVANDIA and glyburide at week 52 were statistically significant.  The pattern of LDL and HDL changes following therapy with AVANDIA in combination with other hypoglycemic agents were generally similar to those seen with AVANDIA in monotherapy.  		none	none	none	none
glyburide	AVANDIA	22	22	false	none	The differences in change from baseline between AVANDIA and glyburide at week 52 were statistically significant.  		none	none	none	none
glyburide	AVANDIA	22	24	false	none	The differences in change from baseline between AVANDIA and glyburide at week 52 were statistically significant.  The pattern of LDL and HDL changes following therapy with AVANDIA in combination with other hypoglycemic agents were generally similar to those seen with AVANDIA in monotherapy.  The changes in triglycerides during therapy with AVANDIA were variable and were generally not statistically different from placebo or glyburide controls.  		none	none	none	none
glyburide	AVANDIA	24	23	false	none	The pattern of LDL and HDL changes following therapy with AVANDIA in combination with other hypoglycemic agents were generally similar to those seen with AVANDIA in monotherapy.  The changes in triglycerides during therapy with AVANDIA were variable and were generally not statistically different from placebo or glyburide controls.  		none	none	none	none
glyburide	AVANDIA	24	22	false	none	The differences in change from baseline between AVANDIA and glyburide at week 52 were statistically significant.  The pattern of LDL and HDL changes following therapy with AVANDIA in combination with other hypoglycemic agents were generally similar to those seen with AVANDIA in monotherapy.  The changes in triglycerides during therapy with AVANDIA were variable and were generally not statistically different from placebo or glyburide controls.  		none	none	none	none
glyburide	AVANDIA	24	24	false	none	The changes in triglycerides during therapy with AVANDIA were variable and were generally not statistically different from placebo or glyburide controls.  		none	none	none	none
glyburide	AVANDIA	15	13	false	none	12.2 Pharmacodynamics    Patients with lipid abnormalities were not excluded from clinical trials of AVANDIA.  In all 26-week controlled trials, across the recommended dose range, AVANDIA as monotherapy was associated with increases in total cholesterol, LDL, and HDL and decreases in free fatty acids.  These changes were statistically significantly different from placebo or glyburide controls (Table 7).  		none	none	none	none
glyburide	AVANDIA	15	14	false	none	In all 26-week controlled trials, across the recommended dose range, AVANDIA as monotherapy was associated with increases in total cholesterol, LDL, and HDL and decreases in free fatty acids.  These changes were statistically significantly different from placebo or glyburide controls (Table 7).  		none	none	none	none
glyburide	AVANDIA	15	16	false	none	These changes were statistically significantly different from placebo or glyburide controls (Table 7).  Increases in LDL occurred primarily during the first 1 to 2 months of therapy with AVANDIA and LDL levels remained elevated above baseline throughout the trials.  		none	none	none	none
glyburide	glimepiride	68	70	false	none	Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  		none	none	none	none
glyburide	glimepiride	69	70	false	none	In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  		none	none	none	none
glyburide	glimepiride	69	71	false	none	In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  		none	none	none	none
glyburide	cholesterol	15	14	false	none	In all 26-week controlled trials, across the recommended dose range, AVANDIA as monotherapy was associated with increases in total cholesterol, LDL, and HDL and decreases in free fatty acids.  These changes were statistically significantly different from placebo or glyburide controls (Table 7).  		none	none	none	none
glyburide	Rosiglitazone	68	66	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  		none	84108	none	C089730
glyburide	Rosiglitazone	68	66	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  		none	84108	none	C089730
glyburide	Rosiglitazone	68	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  		none	84108	none	C089730
glyburide	Rosiglitazone	68	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  		none	84108	none	C089730
glyburide	Rosiglitazone	69	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  		none	84108	none	C089730
glyburide	Rosiglitazone	69	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  		none	84108	none	C089730
glyburide	Rosiglitazone	67	65	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
glyburide	Rosiglitazone	67	65	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
glyburide	Rosiglitazone	67	66	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
glyburide	Rosiglitazone	67	66	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
glyburide	Rosiglitazone	67	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
glyburide	Rosiglitazone	67	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
glyburide	Rosiglitazone	24	25	false	none	The changes in triglycerides during therapy with AVANDIA were variable and were generally not statistically different from placebo or glyburide controls.  12.3 Pharmacokinetics    Maximum plasma concentration (Cmax) and the area under the curve (AUC) of rosiglitazone increase in a dose-proportional manner over the therapeutic dose range (Table 8).  		none	84108	none	C089730
glyburide	Rosiglitazone	24	25	false	none	The changes in triglycerides during therapy with AVANDIA were variable and were generally not statistically different from placebo or glyburide controls.  12.3 Pharmacokinetics    Maximum plasma concentration (Cmax) and the area under the curve (AUC) of rosiglitazone increase in a dose-proportional manner over the therapeutic dose range (Table 8).  		none	84108	none	C089730
metformin	p450	60	62	false	none	Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  		none	none	none	none
metformin	AVANDIA	72	70	true	negative	Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	none	none	none
metformin	AVANDIA	72	71	true	negative	No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	none	none	none
metformin	AVANDIA	72	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	none	none	none
metformin	AVANDIA	72	73	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  		none	none	none	none
metformin	AVANDIA	72	74	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  		none	none	none	none
metformin	AVANDIA	46	45	false	none	As monotherapy and in combination with metformin, AVANDIA improved glycemic control in both males and females.  In metformin combination studies, efficacy was demonstrated with no gender differences in glycemic response.  		none	none	none	none
metformin	AVANDIA	60	59	false	none	No dosage adjustment is therefore required in such patients receiving AVANDIA.  Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  		none	none	none	none
metformin	AVANDIA	60	60	false	none	Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  		none	none	none	none
metformin	AVANDIA	45	45	false	none	As monotherapy and in combination with metformin, AVANDIA improved glycemic control in both males and females.  		none	none	none	none
metformin	glimepiride	72	70	true	negative	Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	none	none	none
metformin	glimepiride	72	71	true	negative	No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	none	none	none
metformin	acarbose	72	73	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  		none	none	none	none
metformin	Rosiglitazone	72	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	84108	none	C089730
metformin	Rosiglitazone	72	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	84108	none	C089730
metformin	Rosiglitazone	46	44	false	none	Gender    Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642).  As monotherapy and in combination with metformin, AVANDIA improved glycemic control in both males and females.  In metformin combination studies, efficacy was demonstrated with no gender differences in glycemic response.  		none	84108	none	C089730
metformin	Rosiglitazone	46	44	false	none	Gender    Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642).  As monotherapy and in combination with metformin, AVANDIA improved glycemic control in both males and females.  In metformin combination studies, efficacy was demonstrated with no gender differences in glycemic response.  		none	84108	none	C089730
metformin	Rosiglitazone	60	58	false	none	Renal Impairment    There are no clinically relevant differences in the pharmacokinetics of rosiglitazone in patients with mild to severe renal impairment or in hemodialysis-dependent patients compared to subjects with normal renal function.  No dosage adjustment is therefore required in such patients receiving AVANDIA.  Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  		none	84108	none	C089730
metformin	Rosiglitazone	60	58	false	none	Renal Impairment    There are no clinically relevant differences in the pharmacokinetics of rosiglitazone in patients with mild to severe renal impairment or in hemodialysis-dependent patients compared to subjects with normal renal function.  No dosage adjustment is therefore required in such patients receiving AVANDIA.  Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  		none	84108	none	C089730
metformin	Rosiglitazone	60	62	false	none	Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  		none	84108	none	C089730
metformin	Rosiglitazone	60	62	false	none	Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  		none	84108	none	C089730
metformin	Rosiglitazone	60	61	false	none	Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  		none	84108	none	C089730
metformin	Rosiglitazone	60	61	false	none	Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  		none	84108	none	C089730
metformin	Rosiglitazone	45	43	false	none	Special Populations    Geriatric    Results of the population pharmacokinetic analysis (n = 716 <65 years; n = 331 ≥65 years) showed that age does not significantly affect the pharmacokinetics of rosiglitazone.  Gender    Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642).  As monotherapy and in combination with metformin, AVANDIA improved glycemic control in both males and females.  		none	84108	none	C089730
metformin	Rosiglitazone	45	43	false	none	Special Populations    Geriatric    Results of the population pharmacokinetic analysis (n = 716 <65 years; n = 331 ≥65 years) showed that age does not significantly affect the pharmacokinetics of rosiglitazone.  Gender    Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642).  As monotherapy and in combination with metformin, AVANDIA improved glycemic control in both males and females.  		none	84108	none	C089730
metformin	Rosiglitazone	45	44	false	none	Gender    Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642).  As monotherapy and in combination with metformin, AVANDIA improved glycemic control in both males and females.  		none	84108	none	C089730
metformin	Rosiglitazone	45	44	false	none	Gender    Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642).  As monotherapy and in combination with metformin, AVANDIA improved glycemic control in both males and females.  		none	84108	none	C089730
gemfibrozil	AVANDIA	65	64	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	none	none	none
gemfibrozil	AVANDIA	65	67	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
gemfibrozil	AVANDIA	66	68	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  		none	none	none	none
gemfibrozil	AVANDIA	66	64	false	none	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	none	none	none
gemfibrozil	AVANDIA	66	67	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	none	none	none
gemfibrozil	Rosiglitazone	65	65	true	positive	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	84108	none	C089730
gemfibrozil	Rosiglitazone	65	65	true	positive	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	84108	none	C089730
gemfibrozil	Rosiglitazone	65	66	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	84108	none	C089730
gemfibrozil	Rosiglitazone	65	66	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	84108	none	C089730
gemfibrozil	Rosiglitazone	65	67	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
gemfibrozil	Rosiglitazone	65	67	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
gemfibrozil	Rosiglitazone	65	63	true	positive	In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	84108	none	C089730
gemfibrozil	Rosiglitazone	65	63	true	positive	In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	84108	none	C089730
gemfibrozil	Rosiglitazone	66	65	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	84108	none	C089730
gemfibrozil	Rosiglitazone	66	65	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	84108	none	C089730
gemfibrozil	Rosiglitazone	66	66	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	84108	none	C089730
gemfibrozil	Rosiglitazone	66	66	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	84108	none	C089730
gemfibrozil	Rosiglitazone	66	67	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
gemfibrozil	Rosiglitazone	66	67	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
p450	AVANDIA	62	64	false	none	12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  		none	none	none	none
p450	AVANDIA	62	60	false	none	Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  		none	none	none	none
p450	Insulin	36	35	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  		none	none	none	none
p450	insulin	36	35	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  		none	5856	none	D007328
p450	insulin	36	35	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  		none	5856	none	D007328
p450	Rosiglitazone	36	35	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  		none	84108	none	C089730
p450	Rosiglitazone	36	35	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  		none	84108	none	C089730
p450	Rosiglitazone	36	36	false	none	In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  		none	84108	none	C089730
p450	Rosiglitazone	36	36	false	none	In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  		none	84108	none	C089730
p450	Rosiglitazone	36	37	false	none	In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  		none	84108	none	C089730
p450	Rosiglitazone	36	37	false	none	In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  		none	84108	none	C089730
p450	Rosiglitazone	62	63	false	none	12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  		none	84108	none	C089730
p450	Rosiglitazone	62	63	false	none	12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  		none	84108	none	C089730
p450	Rosiglitazone	62	62	false	none	12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  		none	84108	none	C089730
p450	Rosiglitazone	62	62	false	none	12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  		none	84108	none	C089730
p450	Rosiglitazone	62	61	false	none	Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  		none	84108	none	C089730
p450	Rosiglitazone	62	61	false	none	Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  		none	84108	none	C089730
AVANDIA	glimepiride	68	70	false	none	Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  		none	none	none	none
AVANDIA	glimepiride	69	70	false	none	In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  		none	none	none	none
AVANDIA	glimepiride	69	71	false	none	In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  		none	none	none	none
AVANDIA	glimepiride	70	70	false	none	Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  		none	none	none	none
AVANDIA	glimepiride	70	71	false	none	Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  		none	none	none	none
AVANDIA	glimepiride	71	70	false	none	Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  		none	none	none	none
AVANDIA	glimepiride	71	71	false	none	No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  		none	none	none	none
AVANDIA	glimepiride	72	70	true	negative	Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	none	none	none
AVANDIA	glimepiride	72	71	true	negative	No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	none	none	none
AVANDIA	glimepiride	73	71	true	negative	No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  		none	none	none	none
AVANDIA	Insulin	13	11	true	negative	The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue.  Rosiglitazone did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance.  12.2 Pharmacodynamics    Patients with lipid abnormalities were not excluded from clinical trials of AVANDIA.  		none	none	none	none
AVANDIA	acarbose	71	73	true	negative	No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  		none	none	none	none
AVANDIA	acarbose	72	73	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  		none	none	none	none
AVANDIA	acarbose	73	73	false	none	Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  		none	none	none	none
AVANDIA	acarbose	74	73	true	negative	Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  		none	none	none	none
AVANDIA	acarbose	75	73	true	negative	Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  		none	none	none	none
AVANDIA	ranitidine	76	77	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	none	none	none
AVANDIA	ranitidine	75	77	true	negative	Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	none	none	none
AVANDIA	insulin	13	11	true	negative	The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue.  Rosiglitazone did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance.  12.2 Pharmacodynamics    Patients with lipid abnormalities were not excluded from clinical trials of AVANDIA.  		none	5856	none	D007328
AVANDIA	insulin	13	11	true	negative	The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue.  Rosiglitazone did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance.  12.2 Pharmacodynamics    Patients with lipid abnormalities were not excluded from clinical trials of AVANDIA.  		none	5856	none	D007328
AVANDIA	cholesterol	13	14	false	none	12.2 Pharmacodynamics    Patients with lipid abnormalities were not excluded from clinical trials of AVANDIA.  In all 26-week controlled trials, across the recommended dose range, AVANDIA as monotherapy was associated with increases in total cholesterol, LDL, and HDL and decreases in free fatty acids.  		none	none	none	none
AVANDIA	cholesterol	14	14	false	none	In all 26-week controlled trials, across the recommended dose range, AVANDIA as monotherapy was associated with increases in total cholesterol, LDL, and HDL and decreases in free fatty acids.  		none	none	none	none
AVANDIA	cholesterol	16	14	false	none	In all 26-week controlled trials, across the recommended dose range, AVANDIA as monotherapy was associated with increases in total cholesterol, LDL, and HDL and decreases in free fatty acids.  These changes were statistically significantly different from placebo or glyburide controls (Table 7).  Increases in LDL occurred primarily during the first 1 to 2 months of therapy with AVANDIA and LDL levels remained elevated above baseline throughout the trials.  		none	none	none	none
AVANDIA	Rosiglitazone	68	66	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	68	66	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	68	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	68	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	69	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	69	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.  In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	70	72	true	negative	Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	70	72	true	negative	Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	71	72	true	negative	No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	71	72	true	negative	No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	64	65	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	64	65	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	64	66	false	none	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	84108	none	C089730
AVANDIA	Rosiglitazone	64	66	false	none	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  		none	84108	none	C089730
AVANDIA	Rosiglitazone	64	63	false	none	In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	64	63	false	none	In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	64	62	false	none	12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	64	62	false	none	12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9.  AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	67	65	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	67	65	false	none	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.  Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	67	66	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	67	66	false	none	Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].  Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	67	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	67	67	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	76	77	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	76	77	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	76	78	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  These results suggest that the absorption of oral rosiglitazone is not altered in conditions accompanied by increases in gastrointestinal pH.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	76	78	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  These results suggest that the absorption of oral rosiglitazone is not altered in conditions accompanied by increases in gastrointestinal pH.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	72	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	72	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	73	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	73	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	13	12	true	negative	Rosiglitazone did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance.  12.2 Pharmacodynamics    Patients with lipid abnormalities were not excluded from clinical trials of AVANDIA.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	13	12	true	negative	Rosiglitazone did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance.  12.2 Pharmacodynamics    Patients with lipid abnormalities were not excluded from clinical trials of AVANDIA.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	74	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	74	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	14	12	true	negative	Rosiglitazone did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance.  12.2 Pharmacodynamics    Patients with lipid abnormalities were not excluded from clinical trials of AVANDIA.  In all 26-week controlled trials, across the recommended dose range, AVANDIA as monotherapy was associated with increases in total cholesterol, LDL, and HDL and decreases in free fatty acids.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	14	12	true	negative	Rosiglitazone did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance.  12.2 Pharmacodynamics    Patients with lipid abnormalities were not excluded from clinical trials of AVANDIA.  In all 26-week controlled trials, across the recommended dose range, AVANDIA as monotherapy was associated with increases in total cholesterol, LDL, and HDL and decreases in free fatty acids.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	75	77	true	negative	Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	75	77	true	negative	Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	45	43	false	none	Special Populations    Geriatric    Results of the population pharmacokinetic analysis (n = 716 <65 years; n = 331 ≥65 years) showed that age does not significantly affect the pharmacokinetics of rosiglitazone.  Gender    Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642).  As monotherapy and in combination with metformin, AVANDIA improved glycemic control in both males and females.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	45	43	false	none	Special Populations    Geriatric    Results of the population pharmacokinetic analysis (n = 716 <65 years; n = 331 ≥65 years) showed that age does not significantly affect the pharmacokinetics of rosiglitazone.  Gender    Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642).  As monotherapy and in combination with metformin, AVANDIA improved glycemic control in both males and females.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	45	44	false	none	Gender    Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642).  As monotherapy and in combination with metformin, AVANDIA improved glycemic control in both males and females.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	45	44	false	none	Gender    Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642).  As monotherapy and in combination with metformin, AVANDIA improved glycemic control in both males and females.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	49	51	false	none	Since the molecular target PPARγ is expressed in adipose tissues, this differentiating characteristic may account, at least in part, for the greater response to AVANDIA in females.  Since therapy should be individualized, no dose adjustments are necessary based on gender alone.  Hepatic Impairment    Unbound oral clearance of rosiglitazone was significantly lower in patients with moderate to severe liver disease (Child-Pugh Class B/C) compared to healthy subjects.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	49	51	false	none	Since the molecular target PPARγ is expressed in adipose tissues, this differentiating characteristic may account, at least in part, for the greater response to AVANDIA in females.  Since therapy should be individualized, no dose adjustments are necessary based on gender alone.  Hepatic Impairment    Unbound oral clearance of rosiglitazone was significantly lower in patients with moderate to severe liver disease (Child-Pugh Class B/C) compared to healthy subjects.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	54	55	false	none	Therapy with AVANDIA should not be initiated if the patient exhibits clinical evidence of active liver disease or increased serum transaminase levels (ALT >2.5X upper limit of normal) at baseline [see Warnings and Precautions (5.6)].  Pediatric    Pharmacokinetic parameters of rosiglitazone in pediatric patients were established using a population pharmacokinetic analysis with sparse data from 96 pediatric patients in a single pediatric clinical trial including 33 males and 63 females with ages ranging from 10 to 17 years (weights ranging from 35 to 178.3 kg).  		none	84108	none	C089730
AVANDIA	Rosiglitazone	54	55	false	none	Therapy with AVANDIA should not be initiated if the patient exhibits clinical evidence of active liver disease or increased serum transaminase levels (ALT >2.5X upper limit of normal) at baseline [see Warnings and Precautions (5.6)].  Pediatric    Pharmacokinetic parameters of rosiglitazone in pediatric patients were established using a population pharmacokinetic analysis with sparse data from 96 pediatric patients in a single pediatric clinical trial including 33 males and 63 females with ages ranging from 10 to 17 years (weights ranging from 35 to 178.3 kg).  		none	84108	none	C089730
AVANDIA	Rosiglitazone	54	53	false	none	Elimination half-life for rosiglitazone was about 2 hours longer in patients with liver disease, compared to healthy subjects.  Therapy with AVANDIA should not be initiated if the patient exhibits clinical evidence of active liver disease or increased serum transaminase levels (ALT >2.5X upper limit of normal) at baseline [see Warnings and Precautions (5.6)].  		none	84108	none	C089730
AVANDIA	Rosiglitazone	54	53	false	none	Elimination half-life for rosiglitazone was about 2 hours longer in patients with liver disease, compared to healthy subjects.  Therapy with AVANDIA should not be initiated if the patient exhibits clinical evidence of active liver disease or increased serum transaminase levels (ALT >2.5X upper limit of normal) at baseline [see Warnings and Precautions (5.6)].  		none	84108	none	C089730
AVANDIA	Rosiglitazone	54	56	false	none	Therapy with AVANDIA should not be initiated if the patient exhibits clinical evidence of active liver disease or increased serum transaminase levels (ALT >2.5X upper limit of normal) at baseline [see Warnings and Precautions (5.6)].  Pediatric    Pharmacokinetic parameters of rosiglitazone in pediatric patients were established using a population pharmacokinetic analysis with sparse data from 96 pediatric patients in a single pediatric clinical trial including 33 males and 63 females with ages ranging from 10 to 17 years (weights ranging from 35 to 178.3 kg).  Population mean CL/F and V/F of rosiglitazone were 3.15 L/hr and 13.5 L, respectively.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	54	56	false	none	Therapy with AVANDIA should not be initiated if the patient exhibits clinical evidence of active liver disease or increased serum transaminase levels (ALT >2.5X upper limit of normal) at baseline [see Warnings and Precautions (5.6)].  Pediatric    Pharmacokinetic parameters of rosiglitazone in pediatric patients were established using a population pharmacokinetic analysis with sparse data from 96 pediatric patients in a single pediatric clinical trial including 33 males and 63 females with ages ranging from 10 to 17 years (weights ranging from 35 to 178.3 kg).  Population mean CL/F and V/F of rosiglitazone were 3.15 L/hr and 13.5 L, respectively.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	23	25	false	none	The pattern of LDL and HDL changes following therapy with AVANDIA in combination with other hypoglycemic agents were generally similar to those seen with AVANDIA in monotherapy.  The changes in triglycerides during therapy with AVANDIA were variable and were generally not statistically different from placebo or glyburide controls.  12.3 Pharmacokinetics    Maximum plasma concentration (Cmax) and the area under the curve (AUC) of rosiglitazone increase in a dose-proportional manner over the therapeutic dose range (Table 8).  		none	84108	none	C089730
AVANDIA	Rosiglitazone	23	25	false	none	The pattern of LDL and HDL changes following therapy with AVANDIA in combination with other hypoglycemic agents were generally similar to those seen with AVANDIA in monotherapy.  The changes in triglycerides during therapy with AVANDIA were variable and were generally not statistically different from placebo or glyburide controls.  12.3 Pharmacokinetics    Maximum plasma concentration (Cmax) and the area under the curve (AUC) of rosiglitazone increase in a dose-proportional manner over the therapeutic dose range (Table 8).  		none	84108	none	C089730
AVANDIA	Rosiglitazone	59	58	false	none	Renal Impairment    There are no clinically relevant differences in the pharmacokinetics of rosiglitazone in patients with mild to severe renal impairment or in hemodialysis-dependent patients compared to subjects with normal renal function.  No dosage adjustment is therefore required in such patients receiving AVANDIA.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	59	58	false	none	Renal Impairment    There are no clinically relevant differences in the pharmacokinetics of rosiglitazone in patients with mild to severe renal impairment or in hemodialysis-dependent patients compared to subjects with normal renal function.  No dosage adjustment is therefore required in such patients receiving AVANDIA.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	59	61	false	none	No dosage adjustment is therefore required in such patients receiving AVANDIA.  Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	59	61	false	none	No dosage adjustment is therefore required in such patients receiving AVANDIA.  Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	24	25	false	none	The changes in triglycerides during therapy with AVANDIA were variable and were generally not statistically different from placebo or glyburide controls.  12.3 Pharmacokinetics    Maximum plasma concentration (Cmax) and the area under the curve (AUC) of rosiglitazone increase in a dose-proportional manner over the therapeutic dose range (Table 8).  		none	84108	none	C089730
AVANDIA	Rosiglitazone	24	25	false	none	The changes in triglycerides during therapy with AVANDIA were variable and were generally not statistically different from placebo or glyburide controls.  12.3 Pharmacokinetics    Maximum plasma concentration (Cmax) and the area under the curve (AUC) of rosiglitazone increase in a dose-proportional manner over the therapeutic dose range (Table 8).  		none	84108	none	C089730
AVANDIA	Rosiglitazone	60	58	false	none	Renal Impairment    There are no clinically relevant differences in the pharmacokinetics of rosiglitazone in patients with mild to severe renal impairment or in hemodialysis-dependent patients compared to subjects with normal renal function.  No dosage adjustment is therefore required in such patients receiving AVANDIA.  Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	60	58	false	none	Renal Impairment    There are no clinically relevant differences in the pharmacokinetics of rosiglitazone in patients with mild to severe renal impairment or in hemodialysis-dependent patients compared to subjects with normal renal function.  No dosage adjustment is therefore required in such patients receiving AVANDIA.  Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	60	62	false	none	Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	60	62	false	none	Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  12.4 Drug-Drug Interactions    Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450    In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	60	61	false	none	Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	60	61	false	none	Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.  Race    Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	30	29	false	none	Administration of rosiglitazone with food resulted in no change in overall exposure (AUC), but there was an approximately 28% decrease in Cmax and a delay in Tmax (1.75 hours).  These changes are not likely to be clinically significant; therefore, AVANDIA may be administered with or without food.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	30	29	false	none	Administration of rosiglitazone with food resulted in no change in overall exposure (AUC), but there was an approximately 28% decrease in Cmax and a delay in Tmax (1.75 hours).  These changes are not likely to be clinically significant; therefore, AVANDIA may be administered with or without food.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	30	31	false	none	These changes are not likely to be clinically significant; therefore, AVANDIA may be administered with or without food.  Distribution    The mean (CV%) oral volume of distribution (Vss/F) of rosiglitazone is approximately 17.6 (30%) liters, based on a population pharmacokinetic analysis.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	30	31	false	none	These changes are not likely to be clinically significant; therefore, AVANDIA may be administered with or without food.  Distribution    The mean (CV%) oral volume of distribution (Vss/F) of rosiglitazone is approximately 17.6 (30%) liters, based on a population pharmacokinetic analysis.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	30	32	false	none	These changes are not likely to be clinically significant; therefore, AVANDIA may be administered with or without food.  Distribution    The mean (CV%) oral volume of distribution (Vss/F) of rosiglitazone is approximately 17.6 (30%) liters, based on a population pharmacokinetic analysis.  Rosiglitazone is approximately 99.8% bound to plasma proteins, primarily albumin.  		none	84108	none	C089730
AVANDIA	Rosiglitazone	30	32	false	none	These changes are not likely to be clinically significant; therefore, AVANDIA may be administered with or without food.  Distribution    The mean (CV%) oral volume of distribution (Vss/F) of rosiglitazone is approximately 17.6 (30%) liters, based on a population pharmacokinetic analysis.  Rosiglitazone is approximately 99.8% bound to plasma proteins, primarily albumin.  		none	84108	none	C089730
glimepiride	acarbose	71	73	true	negative	No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  		none	none	none	none
glimepiride	Rosiglitazone	70	72	true	negative	Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	84108	none	C089730
glimepiride	Rosiglitazone	70	72	true	negative	Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	84108	none	C089730
glimepiride	Rosiglitazone	71	72	true	negative	No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	84108	none	C089730
glimepiride	Rosiglitazone	71	72	true	negative	No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  		none	84108	none	C089730
Insulin	insulin	35	35	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  		none	5856	none	D007328
Insulin	insulin	35	35	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  		none	5856	none	D007328
Insulin	insulin	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  		none	5856	none	D007328
Insulin	insulin	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  		none	5856	none	D007328
Insulin	insulin	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.  		none	5856	none	D007328
Insulin	insulin	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.  		none	5856	none	D007328
Insulin	insulin	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.  		none	5856	none	D007328
Insulin	insulin	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.  		none	5856	none	D007328
Insulin	insulin	3	3	false	none	In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.  		none	5856	none	D007328
Insulin	insulin	3	3	false	none	In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.  		none	5856	none	D007328
Insulin	insulin	3	4	false	none	In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.  Activation of PPARγ nuclear receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization.  		none	5856	none	D007328
Insulin	insulin	3	4	false	none	In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.  Activation of PPARγ nuclear receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization.  		none	5856	none	D007328
Insulin	insulin	4	3	false	none	In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.  Activation of PPARγ nuclear receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization.  		none	5856	none	D007328
Insulin	insulin	4	3	false	none	In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.  Activation of PPARγ nuclear receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization.  		none	5856	none	D007328
Insulin	insulin	4	4	false	none	Activation of PPARγ nuclear receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization.  		none	5856	none	D007328
Insulin	insulin	4	4	false	none	Activation of PPARγ nuclear receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization.  		none	5856	none	D007328
Insulin	insulin	4	6	false	none	Activation of PPARγ nuclear receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization.  In addition, PPARγ-responsive genes also participate in the regulation of fatty acid metabolism.  Insulin resistance is a common feature characterizing the pathogenesis of type 2 diabetes.  		none	5856	none	D007328
Insulin	insulin	4	6	false	none	Activation of PPARγ nuclear receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization.  In addition, PPARγ-responsive genes also participate in the regulation of fatty acid metabolism.  Insulin resistance is a common feature characterizing the pathogenesis of type 2 diabetes.  		none	5856	none	D007328
Insulin	insulin	6	4	false	none	Activation of PPARγ nuclear receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization.  In addition, PPARγ-responsive genes also participate in the regulation of fatty acid metabolism.  Insulin resistance is a common feature characterizing the pathogenesis of type 2 diabetes.  		none	5856	none	D007328
Insulin	insulin	6	4	false	none	Activation of PPARγ nuclear receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization.  In addition, PPARγ-responsive genes also participate in the regulation of fatty acid metabolism.  Insulin resistance is a common feature characterizing the pathogenesis of type 2 diabetes.  		none	5856	none	D007328
Insulin	insulin	6	6	false	none	Insulin resistance is a common feature characterizing the pathogenesis of type 2 diabetes.  		none	5856	none	D007328
Insulin	insulin	6	6	false	none	Insulin resistance is a common feature characterizing the pathogenesis of type 2 diabetes.  		none	5856	none	D007328
Insulin	insulin	6	7	false	none	Insulin resistance is a common feature characterizing the pathogenesis of type 2 diabetes.  The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  		none	5856	none	D007328
Insulin	insulin	6	7	false	none	Insulin resistance is a common feature characterizing the pathogenesis of type 2 diabetes.  The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  		none	5856	none	D007328
Insulin	insulin	6	8	false	none	Insulin resistance is a common feature characterizing the pathogenesis of type 2 diabetes.  The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		none	5856	none	D007328
Insulin	insulin	6	8	false	none	Insulin resistance is a common feature characterizing the pathogenesis of type 2 diabetes.  The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		none	5856	none	D007328
Insulin	insulin	7	6	false	none	Insulin resistance is a common feature characterizing the pathogenesis of type 2 diabetes.  The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  		none	5856	none	D007328
Insulin	insulin	7	6	false	none	Insulin resistance is a common feature characterizing the pathogenesis of type 2 diabetes.  The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  		none	5856	none	D007328
Insulin	insulin	7	7	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  		none	5856	none	D007328
Insulin	insulin	7	7	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  		none	5856	none	D007328
Insulin	insulin	7	8	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		none	5856	none	D007328
Insulin	insulin	7	8	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		none	5856	none	D007328
Insulin	insulin	7	9	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	5856	none	D007328
Insulin	insulin	7	9	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	5856	none	D007328
Insulin	insulin	8	6	false	none	Insulin resistance is a common feature characterizing the pathogenesis of type 2 diabetes.  The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		none	5856	none	D007328
Insulin	insulin	8	6	false	none	Insulin resistance is a common feature characterizing the pathogenesis of type 2 diabetes.  The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		none	5856	none	D007328
Insulin	insulin	8	7	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		none	5856	none	D007328
Insulin	insulin	8	7	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		none	5856	none	D007328
Insulin	insulin	8	8	false	none	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		none	5856	none	D007328
Insulin	insulin	8	8	false	none	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		none	5856	none	D007328
Insulin	insulin	8	9	false	none	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	5856	none	D007328
Insulin	insulin	8	9	false	none	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	5856	none	D007328
Insulin	insulin	9	7	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	5856	none	D007328
Insulin	insulin	9	7	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	5856	none	D007328
Insulin	insulin	9	8	false	none	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	5856	none	D007328
Insulin	insulin	9	8	false	none	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	5856	none	D007328
Insulin	insulin	9	9	false	none	In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	5856	none	D007328
Insulin	insulin	9	9	false	none	In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	5856	none	D007328
Insulin	insulin	9	11	false	none	In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue.  		none	5856	none	D007328
Insulin	insulin	9	11	false	none	In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue.  		none	5856	none	D007328
Insulin	insulin	11	9	false	none	In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue.  		none	5856	none	D007328
Insulin	insulin	11	9	false	none	In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue.  		none	5856	none	D007328
Insulin	insulin	11	11	false	none	The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue.  		none	5856	none	D007328
Insulin	insulin	11	11	false	none	The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue.  		none	5856	none	D007328
Insulin	Rosiglitazone	35	35	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  		none	84108	none	C089730
Insulin	Rosiglitazone	35	35	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  		none	84108	none	C089730
Insulin	Rosiglitazone	35	33	false	none	Metabolism    Rosiglitazone is extensively metabolized with no unchanged drug excreted in the urine.  The major routes of metabolism were N-demethylation and hydroxylation, followed by conjugation with sulfate and glucuronic acid.  All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  		none	84108	none	C089730
Insulin	Rosiglitazone	35	33	false	none	Metabolism    Rosiglitazone is extensively metabolized with no unchanged drug excreted in the urine.  The major routes of metabolism were N-demethylation and hydroxylation, followed by conjugation with sulfate and glucuronic acid.  All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  		none	84108	none	C089730
Insulin	Rosiglitazone	35	36	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  		none	84108	none	C089730
Insulin	Rosiglitazone	35	36	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  		none	84108	none	C089730
Insulin	Rosiglitazone	35	37	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  		none	84108	none	C089730
Insulin	Rosiglitazone	35	37	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  		none	84108	none	C089730
Insulin	Rosiglitazone	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  		none	84108	none	C089730
Insulin	Rosiglitazone	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  		none	84108	none	C089730
Insulin	Rosiglitazone	1	2	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  		none	84108	none	C089730
Insulin	Rosiglitazone	1	2	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  		none	84108	none	C089730
Insulin	Rosiglitazone	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.  		none	84108	none	C089730
Insulin	Rosiglitazone	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.  		none	84108	none	C089730
Insulin	Rosiglitazone	3	2	false	none	Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.  		none	84108	none	C089730
Insulin	Rosiglitazone	3	2	false	none	Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.  		none	84108	none	C089730
Insulin	Rosiglitazone	4	2	false	none	Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.  Activation of PPARγ nuclear receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization.  		none	84108	none	C089730
Insulin	Rosiglitazone	4	2	false	none	Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.  Activation of PPARγ nuclear receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization.  		none	84108	none	C089730
Insulin	Rosiglitazone	6	7	false	none	Insulin resistance is a common feature characterizing the pathogenesis of type 2 diabetes.  The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  		none	84108	none	C089730
Insulin	Rosiglitazone	6	7	false	none	Insulin resistance is a common feature characterizing the pathogenesis of type 2 diabetes.  The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  		none	84108	none	C089730
Insulin	Rosiglitazone	6	8	false	none	Insulin resistance is a common feature characterizing the pathogenesis of type 2 diabetes.  The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		none	84108	none	C089730
Insulin	Rosiglitazone	6	8	false	none	Insulin resistance is a common feature characterizing the pathogenesis of type 2 diabetes.  The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		none	84108	none	C089730
Insulin	Rosiglitazone	7	7	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  		none	84108	none	C089730
Insulin	Rosiglitazone	7	7	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  		none	84108	none	C089730
Insulin	Rosiglitazone	7	8	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		none	84108	none	C089730
Insulin	Rosiglitazone	7	8	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		none	84108	none	C089730
Insulin	Rosiglitazone	7	9	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	84108	none	C089730
Insulin	Rosiglitazone	7	9	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	84108	none	C089730
Insulin	Rosiglitazone	8	7	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		none	84108	none	C089730
Insulin	Rosiglitazone	8	7	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		none	84108	none	C089730
Insulin	Rosiglitazone	8	8	false	none	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		none	84108	none	C089730
Insulin	Rosiglitazone	8	8	false	none	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		none	84108	none	C089730
Insulin	Rosiglitazone	8	9	false	none	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	84108	none	C089730
Insulin	Rosiglitazone	8	9	false	none	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	84108	none	C089730
Insulin	Rosiglitazone	8	10	false	none	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  		none	84108	none	C089730
Insulin	Rosiglitazone	8	10	false	none	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  		none	84108	none	C089730
Insulin	Rosiglitazone	9	7	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	84108	none	C089730
Insulin	Rosiglitazone	9	7	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	84108	none	C089730
Insulin	Rosiglitazone	9	8	false	none	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	84108	none	C089730
Insulin	Rosiglitazone	9	8	false	none	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	84108	none	C089730
Insulin	Rosiglitazone	9	9	false	none	In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	84108	none	C089730
Insulin	Rosiglitazone	9	9	false	none	In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		none	84108	none	C089730
Insulin	Rosiglitazone	9	10	false	none	In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  		none	84108	none	C089730
Insulin	Rosiglitazone	9	10	false	none	In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  		none	84108	none	C089730
Insulin	Rosiglitazone	11	9	false	none	In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue.  		none	84108	none	C089730
Insulin	Rosiglitazone	11	9	false	none	In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue.  		none	84108	none	C089730
Insulin	Rosiglitazone	11	10	false	none	Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue.  		none	84108	none	C089730
Insulin	Rosiglitazone	11	10	false	none	Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue.  		none	84108	none	C089730
Insulin	Rosiglitazone	11	12	true	negative	The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue.  Rosiglitazone did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance.  		none	84108	none	C089730
Insulin	Rosiglitazone	11	12	true	negative	The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue.  Rosiglitazone did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance.  		none	84108	none	C089730
acarbose	Rosiglitazone	73	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  		none	84108	none	C089730
acarbose	Rosiglitazone	73	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  		none	84108	none	C089730
ranitidine	Rosiglitazone	77	77	true	negative	Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	84108	none	C089730
ranitidine	Rosiglitazone	77	77	true	negative	Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  		none	84108	none	C089730
ranitidine	Rosiglitazone	77	78	true	negative	Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  These results suggest that the absorption of oral rosiglitazone is not altered in conditions accompanied by increases in gastrointestinal pH.  		none	84108	none	C089730
ranitidine	Rosiglitazone	77	78	true	negative	Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.  These results suggest that the absorption of oral rosiglitazone is not altered in conditions accompanied by increases in gastrointestinal pH.  		none	84108	none	C089730
insulin	Rosiglitazone	35	35	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	35	35	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	35	33	false	none	Metabolism    Rosiglitazone is extensively metabolized with no unchanged drug excreted in the urine.  The major routes of metabolism were N-demethylation and hydroxylation, followed by conjugation with sulfate and glucuronic acid.  All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	35	33	false	none	Metabolism    Rosiglitazone is extensively metabolized with no unchanged drug excreted in the urine.  The major routes of metabolism were N-demethylation and hydroxylation, followed by conjugation with sulfate and glucuronic acid.  All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	35	36	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	35	36	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	35	37	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	35	37	false	none	All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.  In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.  Excretion    Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	1	2	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  		5856	84108	D007328	C089730
insulin	Rosiglitazone	1	2	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  		5856	84108	D007328	C089730
insulin	Rosiglitazone	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity.  Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	3	2	false	none	Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	3	2	false	none	Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	4	2	false	none	Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.  Activation of PPARγ nuclear receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	4	2	false	none	Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).  In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.  Activation of PPARγ nuclear receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	6	7	false	none	Insulin resistance is a common feature characterizing the pathogenesis of type 2 diabetes.  The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	6	7	false	none	Insulin resistance is a common feature characterizing the pathogenesis of type 2 diabetes.  The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	6	8	false	none	Insulin resistance is a common feature characterizing the pathogenesis of type 2 diabetes.  The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	6	8	false	none	Insulin resistance is a common feature characterizing the pathogenesis of type 2 diabetes.  The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	7	7	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	7	7	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	7	8	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	7	8	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	7	9	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	7	9	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	8	7	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	8	7	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	8	8	false	none	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	8	8	false	none	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	8	9	false	none	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	8	9	false	none	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	8	10	false	none	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	8	10	false	none	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	9	7	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	9	7	false	none	The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues.  Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	9	8	false	none	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	9	8	false	none	Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.  In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	9	9	false	none	In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	9	9	false	none	In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	9	10	false	none	In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	9	10	false	none	In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	11	9	false	none	In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	11	9	false	none	In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues.  Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	11	10	false	none	Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	11	10	false	none	Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis.  The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	11	12	true	negative	The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue.  Rosiglitazone did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance.  		5856	84108	D007328	C089730
insulin	Rosiglitazone	11	12	true	negative	The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue.  Rosiglitazone did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance.  		5856	84108	D007328	C089730
cholesterol	Rosiglitazone	14	12	true	negative	Rosiglitazone did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance.  12.2 Pharmacodynamics    Patients with lipid abnormalities were not excluded from clinical trials of AVANDIA.  In all 26-week controlled trials, across the recommended dose range, AVANDIA as monotherapy was associated with increases in total cholesterol, LDL, and HDL and decreases in free fatty acids.  		none	84108	none	C089730
cholesterol	Rosiglitazone	14	12	true	negative	Rosiglitazone did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance.  12.2 Pharmacodynamics    Patients with lipid abnormalities were not excluded from clinical trials of AVANDIA.  In all 26-week controlled trials, across the recommended dose range, AVANDIA as monotherapy was associated with increases in total cholesterol, LDL, and HDL and decreases in free fatty acids.  		none	84108	none	C089730
